Substances that are recognized by the immune system and induce an immune reaction.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
Differentiation antigens found on thymocytes and on cytotoxic and suppressor T-lymphocytes. CD8 antigens are members of the immunoglobulin supergene family and are associative recognition elements in MHC (Major Histocompatibility Complex) Class I-restricted interactions.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Complex of at least five membrane-bound polypeptides in mature T-lymphocytes that are non-covalently associated with one another and with the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL). The CD3 complex includes the gamma, delta, epsilon, zeta, and eta chains (subunits). When antigen binds to the T-cell receptor, the CD3 complex transduces the activating signals to the cytoplasm of the T-cell. The CD3 gamma and delta chains (subunits) are separate from and not related to the gamma/delta chains of the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA).
Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.
Substances elaborated by bacteria that have antigenic activity.
A bifunctional enzyme that catalyzes the synthesis and HYDROLYSIS of CYCLIC ADP-RIBOSE (cADPR) from NAD+ to ADP-RIBOSE. It is a cell surface molecule which is predominantly expressed on LYMPHOID CELLS and MYELOID CELLS.
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.
A member of the tumor necrosis factor receptor superfamily with specificity for CD40 LIGAND. It is found on mature B-LYMPHOCYTES and some EPITHELIAL CELLS, lymphoid DENDRITIC CELLS. Evidence suggests that CD40-dependent activation of B-cells is important for generation of memory B-cells within the germinal centers. Mutations of the gene for CD40 antigen result in HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 3. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
A membrane glycoprotein and differentiation antigen expressed on the surface of T-cells that binds to CD40 ANTIGENS on B-LYMPHOCYTES and induces their proliferation. Mutation of the gene for CD40 ligand is a cause of HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 1.
Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.
Substances elaborated by viruses that have antigenic activity.
Costimulatory T-LYMPHOCYTE receptors that have specificity for CD80 ANTIGEN and CD86 ANTIGEN. Activation of this receptor results in increased T-cell proliferation, cytokine production and promotion of T-cell survival.
Acidic sulfated integral membrane glycoproteins expressed in several alternatively spliced and variable glycosylated forms on a wide variety of cell types including mature T-cells, B-cells, medullary thymocytes, granulocytes, macrophages, erythrocytes, and fibroblasts. CD44 antigens are the principle cell surface receptors for hyaluronate and this interaction mediates binding of lymphocytes to high endothelial venules. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)
Differentiation antigens expressed on pluripotential hematopoietic cells, most human thymocytes, and a major subset of peripheral blood T-lymphocytes. They have been implicated in integrin-mediated cellular adhesion and as signalling receptors on T-cells.
Glycolipid-anchored membrane glycoproteins expressed on cells of the myelomonocyte lineage including monocytes, macrophages, and some granulocytes. They function as receptors for the complex of lipopolysaccharide (LPS) and LPS-binding protein.
Glycoprotein members of the immunoglobulin superfamily which participate in T-cell adhesion and activation. They are expressed on most peripheral T-lymphocytes, natural killer cells, and thymocytes, and function as co-receptors or accessory molecules in the T-cell receptor complex.
Ratio of T-LYMPHOCYTES that express the CD4 ANTIGEN to those that express the CD8 ANTIGEN. This value is commonly assessed in the diagnosis and staging of diseases affecting the IMMUNE SYSTEM including HIV INFECTIONS.
Glycoproteins expressed on all mature T-cells, thymocytes, and a subset of mature B-cells. Antibodies specific for CD5 can enhance T-cell receptor-mediated T-cell activation. The B-cell-specific molecule CD72 is a natural ligand for CD5. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)
Antigens expressed primarily on the membranes of living cells during sequential stages of maturation and differentiation. As immunologic markers they have high organ and tissue specificity and are useful as probes in studies of normal cell development as well as neoplastic transformation.
A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.
Glycoproteins expressed on cortical thymocytes and on some dendritic cells and B-cells. Their structure is similar to that of MHC Class I and their function has been postulated as similar also. CD1 antigens are highly specific markers for human LANGERHANS CELLS.
Antibodies produced by a single clone of cells.
The 140 kDa isoform of NCAM (neural cell adhesion molecule) containing a transmembrane domain and short cytoplasmic tail. It is expressed by all lymphocytes mediating non-MHC restricted cytotoxicity and is present on some neural tissues and tumors.
Antigens expressed on the cell membrane of T-lymphocytes during differentiation, activation, and normal and neoplastic transformation. Their phenotypic characterization is important in differential diagnosis and studies of thymic ontogeny and T-cell function.
A membrane-bound or cytosolic enzyme that catalyzes the synthesis of CYCLIC ADP-RIBOSE (cADPR) from nicotinamide adenine dinucleotide (NAD). This enzyme generally catalyzes the hydrolysis of cADPR to ADP-RIBOSE, as well, and sometimes the synthesis of cyclic ADP-ribose 2' phosphate (2'-P-cADPR) from NADP.
Surface antigens expressed on myeloid cells of the granulocyte-monocyte-histiocyte series during differentiation. Analysis of their reactivity in normal and malignant myelomonocytic cells is useful in identifying and classifying human leukemias and lymphomas.
A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CTLA-4 ANTIGEN with high specificity and to CD28 ANTIGEN with low specificity. The interaction of CD80 with CD28 ANTIGEN provides a costimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.
Tetraspanin proteins found at high levels in cells of the lymphoid-myeloid lineage. CD53 antigens may be involved regulating the differentiation of T-LYMPHOCYTES and the activation of B-LYMPHOCYTES.
A cell adhesion protein that was originally identified as a heat stable antigen in mice. It is involved in METASTASIS and is highly expressed in many NEOPLASMS.
Zinc-binding metalloproteases that are members of the type II integral membrane metalloproteases. They are expressed by GRANULOCYTES; MONOCYTES; and their precursors as well as by various non-hematopoietic cells. They release an N-terminal amino acid from a peptide, amide or arylamide.
Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CD28 ANTIGEN with high specificity and to CTLA-4 ANTIGEN with low specificity. The interaction of CD86 with CD28 ANTIGEN provides a stimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
Polyomavirus antigens which cause infection and cellular transformation. The large T antigen is necessary for the initiation of viral DNA synthesis, repression of transcription of the early region and is responsible in conjunction with the middle T antigen for the transformation of primary cells. Small T antigen is necessary for the completion of the productive infection cycle.
A tumor necrosis factor receptor subtype found in a variety of tissues and on activated LYMPHOCYTES. It has specificity for FAS LIGAND and plays a role in regulation of peripheral immune responses and APOPTOSIS. Multiple isoforms of the protein exist due to multiple ALTERNATIVE SPLICING. The activated receptor signals via a conserved death domain that associates with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM.
Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.
Membrane antigens associated with maturation stages of B-lymphocytes, often expressed in tumors of B-cell origin.
High-molecular weight glycoproteins uniquely expressed on the surface of LEUKOCYTES and their hemopoietic progenitors. They contain a cytoplasmic protein tyrosine phosphatase activity which plays a role in intracellular signaling from the CELL SURFACE RECEPTORS. The CD45 antigens occur as multiple isoforms that result from alternative mRNA splicing and differential usage of three exons.
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
Substances of fungal origin that have antigenic activity.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
The major group of transplantation antigens in the mouse.
A 67-kDa sialic acid binding lectin that is specific for MYELOID CELLS and MONOCYTE-MACROPHAGE PRECURSOR CELLS. This protein is the smallest siglec subtype and contains a single immunoglobulin C2-set domain. It may play a role in intracellular signaling via its interaction with SHP-1 PROTEIN-TYROSINE PHOSPHATASE and SHP-2 PROTEIN-TYROSINE PHOSPHATASE.
Any part or derivative of a helminth that elicits an immune reaction. The most commonly seen helminth antigens are those of the schistosomes.
Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (ANTIGENS, CD3). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains.
Cell-surface glycoprotein beta-chains that are non-covalently linked to specific alpha-chains of the CD11 family of leukocyte-adhesion molecules (RECEPTORS, LEUKOCYTE-ADHESION). A defect in the gene encoding CD18 causes LEUKOCYTE-ADHESION DEFICIENCY SYNDROME.
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B and APOPTOSIS. They are found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; NEUTROPHILS; EOSINOPHILS; MAST CELLS and NK CELLS. Overexpression of CD30 antigen in hematopoietic malignancies make the antigen clinically useful as a biological tumor marker. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
Glycoproteins found on the membrane or surface of cells.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
Sites on an antigen that interact with specific antibodies.
A subtype of tetraspanin proteins that play a role in cell adhesion, cell motility, and tumor metastasis. CD9 antigens take part in the process of platelet activation and aggregation, the formation of paranodal junctions in neuronal tissue, and the fusion of sperm with egg.
A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.
A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS.
A trisaccharide antigen expressed on glycolipids and many cell-surface glycoproteins. In the blood the antigen is found on the surface of NEUTROPHILS; EOSINOPHILS; and MONOCYTES. In addition, CD15 antigen is a stage-specific embryonic antigen.
Those proteins recognized by antibodies from serum of animals bearing tumors induced by viruses; these proteins are presumably coded for by the nucleic acids of the same viruses that caused the neoplastic transformation.
Established cell cultures that have the potential to propagate indefinitely.
A sialic acid-rich protein and an integral cell membrane mucin. It plays an important role in activation of T-LYMPHOCYTES.
Leukocyte differentiation antigens and major platelet membrane glycoproteins present on MONOCYTES; ENDOTHELIAL CELLS; PLATELETS; and mammary EPITHELIAL CELLS. They play major roles in CELL ADHESION; SIGNAL TRANSDUCTION; and regulation of angiogenesis. CD36 is a receptor for THROMBOSPONDINS and can act as a scavenger receptor that recognizes and transports oxidized LIPOPROTEINS and FATTY ACIDS.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
A group of three different alpha chains (CD11a, CD11b, CD11c) that are associated with an invariant CD18 beta chain (ANTIGENS, CD18). The three resulting leukocyte-adhesion molecules (RECEPTORS, LEUKOCYTE ADHESION) are LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MACROPHAGE-1 ANTIGEN; and ANTIGEN, P150,95.
Large, transmembrane, non-covalently linked glycoproteins (alpha and beta). Both chains can be polymorphic although there is more structural variation in the beta chains. The class II antigens in humans are called HLA-D ANTIGENS and are coded by a gene on chromosome 6. In mice, two genes named IA and IE on chromosome 17 code for the H-2 antigens. The antigens are found on B-lymphocytes, macrophages, epidermal cells, and sperm and are thought to mediate the competence of and cellular cooperation in the immune response. The term IA antigens used to refer only to the proteins encoded by the IA genes in the mouse, but is now used as a generic term for any class II histocompatibility antigen.
A group of antigens that includes both the major and minor histocompatibility antigens. The former are genetically determined by the major histocompatibility complex. They determine tissue type for transplantation and cause allograft rejections. The latter are systems of allelic alloantigens that can cause weak transplant rejection.
Small glycoproteins found on both hematopoietic and non-hematopoietic cells. CD59 restricts the cytolytic activity of homologous complement by binding to C8 and C9 and blocking the assembly of the membrane attack complex. (From Barclay et al., The Leukocyte Antigen FactsBook, 1993, p234)
IMMUNOGLOBULINS on the surface of B-LYMPHOCYTES. Their MESSENGER RNA contains an EXON with a membrane spanning sequence, producing immunoglobulins in the form of type I transmembrane proteins as opposed to secreted immunoglobulins (ANTIBODIES) which do not contain the membrane spanning segment.
Nuclear antigen with a role in DNA synthesis, DNA repair, and cell cycle progression. PCNA is required for the coordinated synthesis of both leading and lagging strands at the replication fork during DNA replication. PCNA expression correlates with the proliferation activity of several malignant and non-malignant cell types.
Oligosaccharide antigenic determinants found principally on NK cells and T-cells. Their role in the immune response is poorly understood.
A transmembrane protein belonging to the tumor necrosis factor superfamily that specifically binds to CD27 ANTIGEN. It is found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; and DENDRITIC CELLS where it plays a role in stimulating the proliferation of CD4-POSITIVE T-LYMPHOCYTES and CD8-POSITIVE T-LYMPHOCYTES.
A ubiquitously expressed complement receptor that binds COMPLEMENT C3B and COMPLEMENT C4B and serves as a cofactor for their inactivation. CD46 also interacts with a wide variety of pathogens and mediates immune response.
A class of animal lectins that bind to carbohydrate in a calcium-dependent manner. They share a common carbohydrate-binding domain that is structurally distinct from other classes of lectins.
Glycoproteins with a wide distribution on hematopoietic and non-hematopoietic cells and strongly expressed on macrophages. CD58 mediates cell adhesion by binding to CD2; (ANTIGENS, CD2); and this enhances antigen-specific T-cell activation.
55-kDa antigens found on HELPER-INDUCER T-LYMPHOCYTES and on a variety of other immune cell types. CD4 antigens are members of the immunoglobulin supergene family and are implicated as associative recognition elements in MAJOR HISTOCOMPATIBILITY COMPLEX class II-restricted immune responses. On T-lymphocytes they define the helper/inducer subset. CD4 antigens also serve as INTERLEUKIN-15 receptors and bind to the HIV receptors, binding directly to the HIV ENVELOPE PROTEIN GP120.
A ubiquitously expressed membrane glycoprotein. It interacts with a variety of INTEGRINS and mediates responses to EXTRACELLULAR MATRIX PROTEINS.
A CD antigen that contains a conserved I domain which is involved in ligand binding. When combined with CD18 the two subunits form MACROPHAGE-1 ANTIGEN.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
An integrin alpha subunit of approximately 150-kDa molecular weight. It is expressed at high levels on monocytes and combines with CD18 ANTIGEN to form the cell surface receptor INTEGRIN ALPHAXBETA2. The subunit contains a conserved I-domain which is characteristic of several of alpha integrins.
The lipopolysaccharide-protein somatic antigens, usually from gram-negative bacteria, important in the serological classification of enteric bacilli. The O-specific chains determine the specificity of the O antigens of a given serotype. O antigens are the immunodominant part of the lipopolysaccharide molecule in the intact bacterial cell. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)
A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*02 allele family.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Progenitor cells from which all blood cells derive.
The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies.
GPI-linked membrane proteins broadly distributed among hematopoietic and non-hematopoietic cells. CD55 prevents the assembly of C3 CONVERTASE or accelerates the disassembly of preformed convertase, thus blocking the formation of the membrane attack complex.
Cell adhesion molecules present on virtually all monocytes, platelets, and granulocytes. CD31 is highly expressed on endothelial cells and concentrated at the junctions between them.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Membrane glycoproteins consisting of an alpha subunit and a BETA 2-MICROGLOBULIN beta subunit. In humans, highly polymorphic genes on CHROMOSOME 6 encode the alpha subunits of class I antigens and play an important role in determining the serological specificity of the surface antigen. Class I antigens are found on most nucleated cells and are generally detected by their reactivity with alloantisera. These antigens are recognized during GRAFT REJECTION and restrict cell-mediated lysis of virus-infected cells.
Tetraspanin proteins that are involved in a variety of cellular functions including BASEMENT MEMBRANE assembly, and in the formation of a molecular complexes on the surface of LYMPHOCYTES.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
A member of the tumor necrosis factor receptor superfamily that is specific for 4-1BB LIGAND. It is found in a variety of immune cell types including activated T-LYMPHOCYTES; NATURAL KILLER CELLS; and DENDRITIC CELLS. Activation of the receptor on T-LYMPHOCYTES plays a role in their expansion, production of cytokines and survival. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
Proteins prepared by recombinant DNA technology.
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles.
Polymorphic class I human histocompatibility (HLA) surface antigens present on almost all nucleated cells. At least 20 antigens have been identified which are encoded by the A locus of multiple alleles on chromosome 6. They serve as targets for T-cell cytolytic responses and are involved with acceptance or rejection of tissue/organ grafts.
Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.
Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION).
Receptors present on activated T-LYMPHOCYTES and B-LYMPHOCYTES that are specific for INTERLEUKIN-2 and play an important role in LYMPHOCYTE ACTIVATION. They are heterotrimeric proteins consisting of the INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT, the INTERLEUKIN-2 RECEPTOR BETA SUBUNIT, and the INTERLEUKIN RECEPTOR COMMON GAMMA-CHAIN.
Sets of cell surface antigens located on BLOOD CELLS. They are usually membrane GLYCOPROTEINS or GLYCOLIPIDS that are antigenically distinguished by their carbohydrate moieties.
Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen.
Ubiquitously-expressed tetraspanin proteins that are found in late ENDOSOMES and LYSOSOMES and have been implicated in intracellular transport of proteins.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
Tetraspanin proteins found associated with LAMININ-binding INTEGRINS. The CD151 antigens may play a role in the regulation of CELL MOTILITY.
A component of the B-cell antigen receptor that is involved in B-cell antigen receptor heavy chain transport to the PLASMA MEMBRANE. It is expressed almost exclusively in B-LYMPHOCYTES and serves as a useful marker for B-cell NEOPLASMS.
An encapsulated lymphatic organ through which venous blood filters.
Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.
Human immune-response or Class II antigens found mainly, but not exclusively, on B-lymphocytes and produced from genes of the HLA-D locus. They are extremely polymorphic families of glycopeptides, each consisting of two chains, alpha and beta. This group of antigens includes the -DR, -DQ and -DP designations, of which HLA-DR is most studied; some of these glycoproteins are associated with certain diseases, possibly of immune etiology.
A membrane-bound tumor necrosis family member found primarily on activated T-LYMPHOCYTES that binds specifically to CD30 ANTIGEN. It may play a role in INFLAMMATION and immune regulation.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
A class of enzymes involved in the hydrolysis of the N-glycosidic bond of nitrogen-linked sugars.
A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.
Molecules on the surface of B- and T-lymphocytes that recognize and combine with specific antigens.
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.
An alpha-integrin subunit found on lymphocytes, granulocytes, macrophages and monocytes. It combines with the integrin beta2 subunit (CD18 ANTIGEN) to form LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Antigens of the virion of the HEPATITIS B VIRUS or the Dane particle, its surface (HEPATITIS B SURFACE ANTIGENS), core (HEPATITIS B CORE ANTIGENS), and other associated antigens, including the HEPATITIS B E ANTIGENS.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
The processes triggered by interactions of ANTIBODIES with their ANTIGENS.
Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen.
The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.)
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
A heterogeneous group of immunocompetent cells that mediate the cellular immune response by processing and presenting antigens to the T-cells. Traditional antigen-presenting cells include MACROPHAGES; DENDRITIC CELLS; LANGERHANS CELLS; and B-LYMPHOCYTES. FOLLICULAR DENDRITIC CELLS are not traditional antigen-presenting cells, but because they hold antigen on their cell surface in the form of IMMUNE COMPLEXES for B-cell recognition they are considered so by some authors.
The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies.
T-cell receptors composed of CD3-associated alpha and beta polypeptide chains and expressed primarily in CD4+ or CD8+ T-cells. Unlike immunoglobulins, the alpha-beta T-cell receptors recognize antigens only when presented in association with major histocompatibility (MHC) molecules.
Immunoglobulins produced in a response to BACTERIAL ANTIGENS.
Class I human histocompatibility (HLA) surface antigens encoded by more than 30 detectable alleles on locus B of the HLA complex, the most polymorphic of all the HLA specificities. Several of these antigens (e.g., HLA-B27, -B7, -B8) are strongly associated with predisposition to rheumatoid and other autoimmune disorders. Like other class I HLA determinants, they are involved in the cellular immune reactivity of cytolytic T lymphocytes.
The altered state of immunologic responsiveness resulting from initial contact with antigen, which enables the individual to produce antibodies more rapidly and in greater quantity in response to secondary antigenic stimulus.
Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.
The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells.
A widely distributed cell surface transmembrane glycoprotein that stimulates the synthesis of MATRIX METALLOPROTEINASES. It is found at high levels on the surface of malignant NEOPLASMS and may play a role as a mediator of malignant cell behavior.
A general term for various neoplastic diseases of the lymphoid tissue.
An albumin obtained from the white of eggs. It is a member of the serpin superfamily.
Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (LAV) antigens.
An inhibitory T CELL receptor that is closely related to CD28 ANTIGEN. It has specificity for CD80 ANTIGEN and CD86 ANTIGEN and acts as a negative regulator of peripheral T cell function. CTLA-4 antigen is believed to play role in inducing PERIPHERAL TOLERANCE.
A promyelocytic cell line derived from a patient with ACUTE PROMYELOCYTIC LEUKEMIA. HL-60 cells lack specific markers for LYMPHOID CELLS but express surface receptors for FC FRAGMENTS and COMPLEMENT SYSTEM PROTEINS. They also exhibit phagocytic activity and responsiveness to chemotactic stimuli. (From Hay et al., American Type Culture Collection, 7th ed, pp127-8)
A widely expressed transmembrane glycoprotein that functions as a METASTASIS suppressor protein. It is underexpressed in a variety of human NEOPLASMS.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
A group of differentiation surface antigens, among the first to be discovered on thymocytes and T-lymphocytes. Originally identified in the mouse, they are also found in other species including humans, and are expressed on brain neurons and other cells.
Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner.
The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc.
Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.
A single, unpaired primary lymphoid organ situated in the MEDIASTINUM, extending superiorly into the neck to the lower edge of the THYROID GLAND and inferiorly to the fourth costal cartilage. It is necessary for normal development of immunologic function early in life. By puberty, it begins to involute and much of the tissue is replaced by fat.
Endogenous tissue constituents that have the ability to interact with AUTOANTIBODIES and cause an immune response.
A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)
Nuclear antigens encoded by VIRAL GENES found in HUMAN HERPESVIRUS 4. At least six nuclear antigens have been identified.
A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes.
A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.
A cell line derived from cultured tumor cells.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
A sex-specific cell surface antigen produced by the sex-determining gene of the Y chromosome in mammals. It causes syngeneic grafts from males to females to be rejected and interacts with somatic elements of the embryologic undifferentiated gonad to produce testicular organogenesis.
A cell adhesion molecule of the immunoglobulin superfamily that is expressed in ENDOTHELIAL CELLS and is involved in INTERCELLULAR JUNCTIONS.
Antigens stimulating the formation of, or combining with heterophile antibodies. They are cross-reacting antigens found in phylogenetically unrelated species.
CD4-positive T cells that inhibit immunopathology or autoimmune disease in vivo. They inhibit the immune response by influencing the activity of other cell types. Regulatory T-cells include naturally occurring CD4+CD25+ cells, IL-10 secreting Tr1 cells, and Th3 cells.
Antibodies obtained from a single clone of cells grown in mice or rats.
Antigenic determinants recognized and bound by the T-cell receptor. Epitopes recognized by the T-cell receptor are often located in the inner, unexposed side of the antigen, and become accessible to the T-cell receptors after proteolytic processing of the antigen.
The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.
A heterodimeric protein that is a cell surface antigen associated with lymphocyte activation. The initial characterization of this protein revealed one identifiable heavy chain (ANTIGENS, CD98 HEAVY CHAIN) and an indeterminate smaller light chain. It is now known that a variety of light chain subunits (ANTIGENS, CD98 LIGHT CHAINS) can dimerize with the heavy chain. Depending upon its light chain composition a diverse array of functions can be found for this protein. Functions include: type L amino acid transport, type y+L amino acid transport and regulation of cellular fusion.
The hepatitis B antigen within the core of the Dane particle, the infectious hepatitis virion.
Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.
The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
The sum of the weight of all the atoms in a molecule.
Technique involving the diffusion of antigen or antibody through a semisolid medium, usually agar or agarose gel, with the result being a precipitin reaction.
A group of the D-related HLA antigens found to differ from the DR antigens in genetic locus and therefore inheritance. These antigens are polymorphic glycoproteins comprising alpha and beta chains and are found on lymphoid and other cells, often associated with certain diseases.
Immunoglobulins produced in response to VIRAL ANTIGENS.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
A glycolipid, cross-species antigen that induces production of antisheep hemolysin. It is present on the tissue cells of many species but absent in humans. It is found in many infectious agents.
Elements of limited time intervals, contributing to particular results or situations.
The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.
An inhibitory B7 antigen that has specificity for the T-CELL receptor PROGRAMMED CELL DEATH 1 PROTEIN. CD274 antigen provides negative signals that control and inhibit T-cell responses and is found at higher than normal levels on tumor cells, suggesting its potential role in TUMOR IMMUNE EVASION.
Serologic tests based on inactivation of complement by the antigen-antibody complex (stage 1). Binding of free complement can be visualized by addition of a second antigen-antibody system such as red cells and appropriate red cell antibody (hemolysin) requiring complement for its completion (stage 2). Failure of the red cells to lyse indicates that a specific antigen-antibody reaction has taken place in stage 1. If red cells lyse, free complement is present indicating no antigen-antibody reaction occurred in stage 1.
A species of POLYOMAVIRUS originally isolated from Rhesus monkey kidney tissue. It produces malignancy in human and newborn hamster kidney cell cultures.
Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
Antigens that exist in alternative (allelic) forms in a single species. When an isoantigen is encountered by species members who lack it, an immune response is induced. Typical isoantigens are the BLOOD GROUP ANTIGENS.
Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure MONOCLONAL ANTIBODIES or T-cell products, identical to those produced by the immunologically competent parent cell.
A melanosome-associated protein that plays a role in the maturation of the MELANOSOME.
The genetic region which contains the loci of genes which determine the structure of the serologically defined (SD) and lymphocyte-defined (LD) TRANSPLANTATION ANTIGENS, genes which control the structure of the IMMUNE RESPONSE-ASSOCIATED ANTIGENS, HUMAN; the IMMUNE RESPONSE GENES which control the ability of an animal to respond immunologically to antigenic stimuli, and genes which determine the structure and/or level of the first four components of complement.
Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type.
A technique that combines protein electrophoresis and double immunodiffusion. In this procedure proteins are first separated by gel electrophoresis (usually agarose), then made visible by immunodiffusion of specific antibodies. A distinct elliptical precipitin arc results for each protein detectable by the antisera.
Form of passive immunization where previously sensitized immunologic agents (cells or serum) are transferred to non-immune recipients. When transfer of cells is used as a therapy for the treatment of neoplasms, it is called adoptive immunotherapy (IMMUNOTHERAPY, ADOPTIVE).

Plasma-soluble CD30 in childhood tuberculosis: effects of disease severity, nutritional status, and vitamin A therapy. (1/479)

Plasma-soluble CD30 (sCD30) is the result of proteolytic splicing from the membrane-bound form of CD30, a putative marker of type 2 cytokine-producing cells. We measured sCD30 levels in children with tuberculosis, a disease characterized by prominent type 1 lymphocyte cytokine responses. We postulated that disease severity and nutritional status would alter cytokine responses and therefore sCD30 levels. Samples from South African children enrolled prospectively at the time of diagnosis of tuberculosis were analyzed. (Patients were originally enrolled in a randomized, double-blind placebo-controlled study of the effects of oral vitamin A supplementation on prognosis of tuberculosis.) Plasma samples collected at the time of diagnosis and 6 and 12 weeks later (during antituberculosis therapy) were analyzed. sCD30 levels were measured by enzyme immunoassay. The 91 children included in the study demonstrated high levels of sCD30 at diagnosis (median, 98 U/liter; range, 11 to 1,569 U/liter). Although there was a trend toward higher sCD30 levels in more severe disease (e.g., culture-positive disease or miliary disease), this was not statistically significant. Significantly higher sCD30 levels were demonstrated in the presence of nutritional compromise: the sCD30 level was higher in patients with a weight below the third percentile for age, in those with clinical signs of kwashiorkor, and in those with a low hemoglobin content. There was minimal change in the sCD30 level after 12 weeks of therapy, even though patients improved clinically. However, changes in sCD30 after 12 weeks differed significantly when 46 patients (51%) who received vitamin A were compared with those who had received a placebo. Vitamin A-supplemented children demonstrated a mean (+/- standard error of the mean) decrease in sCD30 by a factor of 0.99 +/- 0.02 over 12 weeks, whereas a factor increase of 1.05 +/- 0.02 was demonstrated in the placebo group (P = 0.02). We conclude that children with tuberculosis had high sCD30 levels, which may reflect the presence of a type 2 cytokine response. Nutritional compromise was associated with higher sCD30 levels. Vitamin A therapy resulted in modulation of sCD30 levels over time.  (+info)

Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). (2/479)

Anaplastic large cell lymphoma (ALCL) is a heterogeneous family of lymphoid tumours, among which the T and null cell types were recently listed in the REAL classification as a distinct entity. Reports on autologous stem cell transplantation (ASCT) in this group are only occasional. Sixty-four patients with T and null cell ALCL from 25 European centres had been registered with the European Group for Blood and Marrow Transplantation (EBMT) at the onset of this study. The median age was 25 years (range 3.2-53.0). Thirty of the 64 patients (47%) were in complete remission (CR), 18 (28%) in partial remission (PR), and the remaining 16 (25%) had a more advanced or chemotherapy-refractory disease at transplant. Eighty-one percent of the patients were conditioned with chemotherapy alone and 75% received marrow stem cells. All the patients transplanted in first CR (15), except one, maintained the CR over time; six of 15 transplanted in CR subsequent to first, six of 18 transplanted in PR and 14 of 16 transplanted in refractory or relapsed disease progressed. Actuarial overall survival (OS) at 10 years is 70%. Multivariate analysis showed that good status at transplant, younger age, absence of B symptoms and absence of extranodal disease indicated a better prognosis. These data suggest that ASCT should be considered as a possible treatment for chemosensitive patients in CR or PR. However, definitive conclusions cannot be drawn from this study and a prospective randomised trial between ASCT and conventional chemotherapy may be indicated.  (+info)

ALK+ lymphoma: clinico-pathological findings and outcome. (3/479)

A distinct pathologic entity (ALK+ lymphoma) that is characterized by expression of the anaplastic lymphoma kinase (ALK) protein has recently emerged within the heterogeneous group of CD30(+) anaplastic large-cell lymphomas. Information on clinical findings and treatment outcome of ALK+ lymphoma is still limited, and no data are available concerning the value of the International Prognostic Index when applied to this homogeneous disease entity. To clarify these issues, a recently developed monoclonal antibody ALKc (directed against the cytoplasmic portion of ALK) was used to detect expression of the ALK protein in paraffin-embedded biopsies from 96 primary, systemic T/null anaplastic large-cell lymphomas, and the ALK staining pattern was correlated with morphological features, clinical findings, risk factors (as defined by the International Prognostic Index), and outcome in 78 patients (53 ALK+ and 25 ALK-). Strong cytoplasmic and/or nuclear ALK positivity was detected in 58 of 96 ALCL cases (60.4%), and it was associated with a morphological spectrum (common type, 82.7%; giant cell, 3.5%; lymphohistiocytic, 8. 6%; and small cell, 5.2%) that reflected the ratio of large anaplastic elements (usually showing cytoplasmic and nuclear ALK positivity) to small neoplastic cells (usually characterized by nucleus-restricted ALK expression). Clinically, ALK+ lymphoma mostly occurred in children and young adults (mean age, 22.01 +/- 10.87 years) with a male predominance (male/female [M/F] ratio, 3.0) that was particularly striking in the second-third decades of life (M/F ratio, 6.5) and usually presented as an aggressive, stage III-IV disease, frequently associated with systemic symptoms (75%) and extranodal involvement (60%), especially skin (21%), bone (17%), and soft tissues (17%). As compared with ALK+ lymphoma, ALK- cases occurred in older individuals (mean age, 43.33 +/- 16.15 years) and showed a lower M/F ratio (0.9) as well as lower incidence of stage III-IV disease and extranodal involvement at presentation. Overall survival of ALK+ lymphoma was far better than that of ALK- anaplastic large-cell lymphoma (71% +/- 6% v 15% +/- 11%, respectively). However, within the good prognostic category of ALK+ lymphoma, survival was 94% +/- 5% for the low/low intermediate risk group (age-adjusted International Prognostic Index, 0 to 1) and 41% +/- 12% for the high/high intermediate risk group (age-adjusted International Prognostic Index, >/=2). Multivariate analysis identified ALK expression and the International Prognostic Index as independent variables that were able to predict survival among T/null primary, systemic anaplastic large-cell lymphoma. Thus, we suggest that such parameters should be taken into consideration for the design of future clinical trials.  (+info)

The T-cell activation markers CD30 and OX40/CD134 are expressed in nonoverlapping subsets of peripheral T-cell lymphoma. (4/479)

The tumor necrosis factor (TNF) receptor family includes several important markers of activation in T cells. We examined expression patterns of two T-cell-associated members of these receptors, namely CD30 and OX40/CD134, in 148 cases of T-cell lymphoma to identify possible objective immunohistochemical criteria for subclassification of these tumors. CD30 expression was characteristic of tumors with an anaplastic (46/47 cases [98%]) or large-cell (10/21 [48%]) morphology and was seen in only scattered cells in other tumor types. In contrast, large numbers of OX40/CD134(+) tumors cells were typical of angioimmunoblastic lymphoma (15/16 [94%]), angiocentric lymphoma (4/4), a subset of large-cell lymphomas (10/21 [48%]), and lymphomas with a prominent histiocytic component (6/7 [86%]). Strong OX40/CD134 and CD30 coexpression was seen in only 4% of tumors, typically those with an anaplastic/Hodgkin's-like appearance. OX40/CD134 expression was characteristic of tumors composed of activated CD4(+) T cells and was not seen in small-cell T-cell lymphomas, lymphoblastic lymphomas, or other tumor types, including B-cell lymphomas or carcinomas. These results suggest that immunostaining for OX40/CD134 may be helpful in subclassification of peripheral T-cell lymphomas and that the patterns of TNF receptor family expression in these tumors may parallel those seen within nonneoplastic helper T-cell subsets.  (+info)

Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. (5/479)

Several members of the tumour necrosis factor receptor (TNF-R) superfamily can induce cell death. For TNF-R1, Fas/APO-1, DR3, DR6, TRAIL-R1 and TRAIL-R2, a conserved 'death domain' in the intracellular region couples these receptors to activation of caspases. However, it is not yet known how TNF receptor family members lacking a death domain, such as TNF-R2, CD40, LT-betaR, CD27 or CD30, execute their death-inducing capability. Here we demonstrate in different cellular systems that cytotoxic effects induced by TNF-R2, CD40 and CD30 are mediated by endogenous production of TNF and autotropic or paratropic activation of TNF-R1. In addition, stimulation of TNF-R2 and CD40 synergistically enhances TNF-R1-induced cytotoxicity. These findings describe a novel pro-apoptotic mechanism induced by some members of the TNF-R family.  (+info)

An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line. (6/479)

The human CD30 receptor is highly overexpressed on the surface of Hodgkin Reed-Sternberg cells and has been shown to be an excellent target for selective immunotherapy using monoclonal antibody-based agents such as immunotoxins. To construct a new recombinant immunotoxin for possible clinical use in patients with Hodgkin's lymphoma, we have chosen the murine anti-CD30 hybridoma Ki-4 to generate a high-affinity Ki-4 single-chain variable fragment (scFv). Hybridoma V-genes were polymerase chain reaction-amplified, assembled, cloned and expressed as a mini-library for display on filamentous phage. Functional Ki-4 scFv were obtained by selection of binding phage on the Hodgkin lymphoma-derived, CD30-expressing cell line L540Cy. The selected recombinant Ki-4 scFv was shown to specifically bind to an overlapping epitope on the CD30 antigen with binding kinetics similar to those of the original antibody. The Ki-4 scFv was subsequently fused to a deletion mutant of Pseudomonas exotoxin A (ETA'). The resulting immunotoxin Ki-4(scFv)-ETA' specifically binds to CD30+ L540Cy cells and inhibits the protein synthesis by 50% at a concentration (IC50) of 43 pM. This recombinant immunotoxin is a promising candidate for further clinical evaluation in patients with Hodgkin's lymphoma or other CD30+ malignancies.  (+info)

CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. (7/479)

The biological function of CD30 in the thymus has been only partially elucidated, although recent data indicate that it may be involved in negative selection. Because CD30 is expressed only by a small subpopulation of medullary thymocytes, we generated transgenic (Tg) mice overexpressing CD30 in T lymphocytes to further address its role in T cell development. CD30 Tg mice have normal thymic size with a normal number and subset distribution of thymocytes. In vitro, in the absence of CD30 ligation, thymocytes of CD30 Tg mice have normal survival and responses to apoptotic stimuli such as radiation, dexamethasone, and Fas. However, in contrast to controls, CD30 Tg thymocytes are induced to undergo programmed cell death (PCD) upon cross-linking of CD30, and the simultaneous engagement of TCR and CD30 results in a synergistic increase in thymic PCD. CD30-mediated PCD requires caspase 1 and caspase 3, is not associated with the activation of NF-kappaB or c-Jun, but is totally prevented by Bcl-2. Furthermore, CD30 overexpression enhances the deletion of CD4+/CD8+ thymocytes induced by staphylococcal enterotoxin B superantigen and specific peptide. These findings suggest that CD30 may act as a costimulatory molecule in thymic negative selection.  (+info)

IL-12 receptor beta2 and CD30 expression in paranasal sinus mucosa of patients with chronic sinusitis. (8/479)

The aetiology of chronic sinusitis is still poorly understood. The expression of T-helper 1 (Th1) and T-helper 2 (Th2) cell markers, interleukin (IL)-12 receptor beta2 subunit (IL-12Rbeta2) messenger ribonucleic acid (mRNA) and CD30, respectively, were investigated in the paranasal sinus mucosa of patients with chronic sinusitis in an attempt to elucidate the involvement of Th1 and Th2 cells in this disease. Anterior ethmoidal mucosae were surgically obtained from two groups of patients with chronic sinusitis: those who had allergic rhinitis (allergic group, n=11) and those without allergy (nonallergic group, n=11). IL-12Rbeta2 mRNA was quantified by means of the reverse transcription polymerase chain reaction, and CD30-positive cells were examined immunohistochemically. Both IL-12Rbeta2 mRNA and CD30 were expressed in the sinus mucosa of the allergic and nonallergic groups. The proportion of mononuclear cells which were CD30-positive in the sinus mucosa was significantly greater in the allergic than in the nonallergic group. The expression levels of IL-12Rbeta2 mRNA were virtually equivalent in both groups. These results suggest a T-helper 2-dominated mucosal reaction in the allergic compared to the nonallergic group, and indicate T-helper 1 activity in the sinus mucosa of both groups. The ubiquity of T-helper 1 cells suggests that they play a role in maintaining local mucosal defences against foreign antigens, which continually enter the upper respiratory tract.  (+info)

Monomethyl auristatin E (MMAE; Vedotin) is an antimitotic agent which inhibits cell division by blocking the polymerisation of tubulin. Buy Microtubule inhibitor Monomethyl auristatin E (MMAE, Vedotin) from AbMole BioScience.
Monomethyl auristatin E (MMAE) is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which directs it to the cancer cells. In International Nonproprietary Names for MMAE-MAB-conjugates, the name vedotin refers to MMAE plus its linking structure to the antibody.[1] It is a potent antimitotic drug derived from peptides occurring in marine shell-less mollusc Dolabella auricularia called dolastatins which show potent activity in preclinical studies, both in vitro and in vivo, against a range of lymphomas, leukemia and solid tumors. These drugs show potency of up to 200 times that of vinblastine, another antimitotic drug used for Hodgkin lymphoma as well as other types of cancer.[2] MMAE is actually desmethyl-auristatin E; that is, the N-terminal amino group has only one methyl substituent instead of two as in auristatin E itself.[2] ...
Pan, L.-Q., Wang, H.-B., Xie, Z.-M., Li, Z.-H., Tang, X.-J., Xu, Y.-C., Zhang, C., Naranmandura, H. and Chen, S.-Q. (2013), Novel Conjugation of Tumor-Necrosis-Factor-Related Apoptosis-Inducing Ligand (TRAIL) with Monomethyl Auristatin E for Efficient Antitumor Drug Delivery. Adv. Mater., 25: 4718-4722. doi: 10.1002/adma.201301385 ...
PRIMARY OBJECTIVES:. I. To determine the tolerability of brentuximab vedotin given in combination with standard chemotherapy (anaplastic large cell lymphoma [ALCL]99) and to determine the tolerability of crizotinib given in combination with chemotherapy (ALCL99).. II. To estimate the event free survival (EFS) of Arm brentuximab vedotin (BV) and Arm crizotinib (CZ) and contrast these to historical control data.. SECONDARY OBJECTIVES:. I. To determine the prognostic significance of minimal disseminated disease (MDD) at diagnosis and minimal residual disease (MRD) as measured by real-time (RT)-polymerase chain reaction (PCR) in peripheral blood.. OUTLINE: Patients are assigned or randomized into 1 of 2 treatment arms.. ARM BV:. COURSE A (COURSES 1, 3, AND 5): Patients receive brentuximab vedotin intravenously (IV) over 30 minutes on day 1, dexamethasone orally (PO) twice daily (BID) or IV on days 1-5, ifosfamide IV over 60 minutes on days 1-5, methotrexate IV over 3 hours on day 1, cytarabine IV ...
Health Canada Approves ADCETRIS® (Brentuximab Vedotin) for the Treatment of Relapsed or Refractory Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL)
Purpose: The antibody-drug conjugate (ADC) brentuximab vedotin comprises a CD30-directed antibody covalently attached to the potent antimicrotubule agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. This study explored the safety, maximum tolerated dose (MTD), and activity of weekly dosing of brentuximab vedotin in patients with relapsed or refractory CD30-positive hematologic malignancies. Experimental Design: In this phase 1 dose-escalation study, brentuximab vedotin was administered intravenously on Days 1, 8, and 15, of each 28-day cycle at doses ranging from 0.4 to 1.4 mg/kg. Forty-four patients were enrolled: 38 with Hodgkin lymphoma, 5 with systemic anaplastic large cell lymphoma, and 1 with peripheral T-cell lymphoma - not otherwise specified. Doses were escalated in increments of 0.2 mg/kg until dose-limiting toxicity (DLT) was observed. Patients were monitored for anti-therapeutic antibodies and pharmacokinetic parameters. Antitumor assessments were performed every 2 ...
Technology Appraisal Guidance No. 446. Source: National Institute for Health and Care Excellence. 1. Guidance. 1.1 Brentuximab vedotin is recommended as an option for treating CD30-positive Hodgkin lymphoma in adults, only if:. they have relapsed or refractory disease after autologous stem cell transplant and. the company provides brentuximab vedotin at the price agreed with NHS England in the commercial access agreement.. 1.2 Brentuximab vedotin is recommended for use within the Cancer Drugs Fund as an option for treating CD30-positive Hodgkin lymphoma in adults, only if:. ...
We report the case of a 61-year-old woman who developed an anaplastic CD30+ cutaneous T-cell lymphoma during oral cyclosporine (CsA) therapy for recalcitrant psoriasis. Two months after CsA discontinuation, clinical and histological resolution of the
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory CD30‑positive Hodgkin lymphoma in adults
Carbonic anhydrase 9 (CAIX, carbonic anhydrase 9) is a cell surface glycoprotein that is expressed in many different tumors and yet restricted in normal tissues to the gastrointestinal tract. It is upregulated by hypoxia, and correlates with tumor grade and poor survival in several tumor indications. Monoclonal antibodies with single digit nanomolar binding affinity for CAIX were derived by panning with the recombinant ecto-domain of CAIX against the MorphoSys HUCAL Gold library of human Fabs. Highest affinity Fabs were converted to full length IgGs and subjected to further characterization based upon their avidity and selectivity for CAIX, their capacity to undergo internalization in CAIX expressing cell lines and their selective localization to CAIX positive human xenografted tumors when administered to mice as fluorescent-conjugates. Through this selection process, the 3ee9 monoclonal antibody was identified which upon conjugation to Monomethyl Auristatin E (MMAE) through a self-imolative ...
Seattle Genetics and Millennium: The Takeda Oncology Company Announce Strategic Collaboration for Novel Late-Stage Lymphoma Program Brentuximab Vedotin (SGN-35) Seattle Genetics to Receive $60
BREVITY:A phase II study of brentuximab vedotin using a response adapted design in patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity
Looking for medication to treat systemic+anaplastic+large+cell+lymphoma? Find a list of current medications, their possible side effects, dosage, and efficacy when used to treat or reduce the symptoms of systemic+anaplastic+large+cell+lymphoma
Ki-1 anaplastic large cell lymphoma (ALCL) commonly affects the skin, lymph nodes, and bone. Primary ALCL of the alimentary tract is rare. The authors describe a case of primary ALCL of the duodenum...
PRIMARY OBJECTIVES:. I. To estimate the maximum tolerated dose (MTD) and/or recommended Phase 2 dose of brentuximab vedotin in combination with gemcitabine administered every three weeks to children with relapsed or primary refractory Hodgkin lymphoma (HL).. II. To define and describe the toxicities of brentuximab vedotin in combination with gemcitabine administered on this schedule.. III. To determine the complete response (CR) rate after treatment with four cycles of gemcitabine with brentuximab vedotin among patients with relapsed or refractory HL.. SECONDARY OBJECTIVES:. I. To preliminarily define the antitumor activity of brentuximab vedotin in combination with gemcitabine within the confines of a Phase 1 study.. II. To describe the overall response rate (ORR) after 4 cycles of therapy among patients with relapsed or refractory HL.. III. To describe the proportion of patients with HL able to mobilize an adequate yield of cluster of differentiation (CD) 34+ stem cells after gemcitabine with ...
Previously, several groups have investigated the expression of MUC1 in malignant lymphomas. However, data on MUC1 expression in lymphomas are skewed in favour of the E29 (anti-EMA) monoclonal antibody,37 the one used most frequently in haematopathology. Furthermore, E29 does not distinguish between hyperglycosylated and hypoglycosylated MUC129; therefore, little is known about the MUC1 glycoforms present on lymphoma tumour cells. In our present study, we have used a panel of five monoclonal antibodies to study the expression and extent of glycosylation of MUC1 in ALCL and classic HD. As already described, these five antibodies all react to the immunodominant PDTRP(AP) sequence within the MUC1 protein core, but have different binding affinities, depending on the mode of glycosylation of MUC1.26,29,30,46. Our results show that MUC1, as detected by E29, DF3, and 139H2, is preferentially expressed in a subtype of systemic nodal ALCL, characterised by the presence of the ALK protein. E29 and DF3 ...
There are 6 clinical trials for anaplastic large cell lymphoma, ALK-negative, of which 6 are open and 0 are completed or closed. Of the trials that contain anaplastic large cell lymphoma, ALK-negative as an inclusion criterion, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open). TNFRSF8, ALK, and CD7 are the most frequent gene inclusion criteria for anaplastic large cell lymphoma, ALK-negative clinical trials [3]. ...
Primary cutaneous CD30+ anaplastic large cell lymphoma, Authors: Antonio Cuneo, Gianluigi Castoldi. Published in: Atlas Genet Cytogenet Oncol Haematol.
Shanghai, CHINA and Osaka, JAPAN May 15, 2020 - Takeda China announced today that ADCETRIS® (brentuximab vedotin) has been officially approved by Chinas National Medical Products Administration (NMPA) for use in adult patients with relapsed or refractory systemic Anaplastic Large Cell Lymphoma (sALCL) or CD30-positive Hodgkin Lymphoma.
Brentuximab vedotin is a type of targeted therapy used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Millennium and Seattle Genetics Highlight Data from ADCETRIS® (Brentuximab Vedotin) Trial in Patients with Newly Diagnosed Systemic Anaplastic Large Cell Lymphoma
The goal of this clinical research study is learn more about the safety of SGN-35 (brentuximab vedotin) in patients who participated in 2009-0851, were on placebo, and whose HL has gotten worse. Another goal of this study is to allow other patients with HL and ALCL whose disease has come back or is not getting better on another treatment, access to brentuximab vedotin.
TY - JOUR. T1 - Association between CD14 polymorphisms and serum soluble CD14 levels. T2 - Effect of atopy and endotoxin inhalation. AU - LeVan, Tricia D.. AU - Michel, Olivier. AU - Dentener, Mieke. AU - Thorn, Jörgen. AU - Vertongen, Francoise. AU - Beijer, Lena. AU - Martinez, Fernando D.. N1 - Funding Information: Supported by grants from the National Institutes of Health (ES-00386 to T.D.L. and HL61892 to F.D.M.), the American Heart Association (9960342Z to T.D.L.), and Astra Zeneca Belgium (to O.M.). Copyright: Copyright 2018 Elsevier B.V., All rights reserved.. PY - 2008/2. Y1 - 2008/2. N2 - Background: A prerequisite for activation of the innate immune response by endotoxin is its binding to CD14. Objective: The aim of this study was to evaluate the role of CD14 polymorphisms, atopy, and inhaled endotoxin in modulating serum CD14 levels. Methods: Healthy volunteers (n = 88) were genotyped for CD14 polymorphisms at the -1619, -1359, and -159 loci, relative to the transcription start ...
Press Release issued Dec 26, 2014: Global Markets Directs, Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2014, provides an overview of the Anaplastic Large Cell Lymphoma (ALCL)s therapeutic pipeline.
Brentuximab vedotin - Intravenous : Brentuximab vedotin is used on its own or together with other medicines to treat cancer of the blood and lymph tissue.
A 15-year-old boy presented to us with a 4-month history of fever with worsening dyspnea since 1 month. His contrast-enhanced computed tomography scan of the thorax showed bilateral endobronchial lesions with complete collapse-consolidation of the left lung and partial collapse of the right lower lobe. His fiberoptic bronchoscopy guided biopsy had been reported in outside hospital as a neuroendocrine tumor. Due to worsening breathlessness, he had to be intubated. We repeated the endobronchial biopsy and combined with outside slides and blocks, was diagnosed to have an anaplastic lymphoma kinase-1 positive anaplastic large cell lymphoma (ALCL ...
More than half of patients with relapsed or refractory systemic anaplastic large-cell lymphoma (ALCL) treated with the CD30-directed antibody-drug conjugate brentuximab vedotin achieve a complete remission.
Adult patients with CD30+ relapsed/refractory (R/R) Hodgkin Lymphoma (HL) after ASCT - National Institute for Health and Care Excellence (NICE) recommend long-term funding for brentuximab vedotin
Prince, H Miles; Kim, Youn H; Horwitz, Steven M; et al; Dummer, Reinhard (2017). Brentuximab vedotin or physicians choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet, 390(10094):555-566. ...
Brentuximab Vedotin and CHP Combination Leads to Lasting Remissions in Peripheral T-Cell Lymphomas - From the Blood Journals, News, Written in Blood - ASH Clinical News
Potentials of brentuximab vedotin in the treatment of relapse/refractory cutaneous T-cell lymphomas: literature review and authors observation
Patients over the age of 60 years with classical Hodgkin lymphoma (cHL) often experience treatment-related toxicities with standard frontline chemotherapy or multiagent regimens, said Christopher A. Yasenchak, MD, who added that a novel combination with brentuximab vedotin (Adcetris) and nivolumab (Opdivo) could provide a more tolerable option for this population.
Anaplastic large cell lymphoma (ALCL) is an aggressive CD30+ T-cell lymphoma that accounts for 2-8% and 10-15% of non-Hodgkin lymphomas in adults and children, respectively. The currently used standard therapy for anaplastic lymphoma kinase (ALK, a member of the insulin receptor superfamily) positive ALCL has limited effectiveness, resulting in a substantial percentage of cases with poor outcomes, either failing to enter remission or relapse within a few months after starting treatment. Thus, there is a clear unmet clinical need for developing novel, effective and safer therapeutic strategies for ALCL. Nucleophosmin 1 (NPM1) is a nucleolar phosphoprotein, which functions as a molecular chaperone for proteins and nucleic acids. Approximately 50% of ALCL cases are positive for the NPM1-ALK fusion chimera generated by the t(2;5) chromosomal translocation. The oligomerization domain of NPM1 in the fusion protein NPM1-ALK mediates the ligand-independent dimerization of chimeric protein, which results ...
polyneuropathy, ALT/AST increased, rash, and back pain. ADCETRIS (brentuximab vedotin) U.S. Important Safety Information BOXED WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) ...
City of Hope research-led study reports on five-year survival data, suggests that the targeted therapy brentuximab vedotin (BV) should be standard of care for patients with relapsed or treatment-resistant Hodgkin lymphoma.
Brentuximab Vedotin Plus Dacarbazine or Bendamustine: New Options for Older Patients with Hodgkin Lymphoma? - Meeting News, Special Edition - ASH Clinical News
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced results from a phase I clinical trial of ADCETRIS (brentuximab vedotin) in combination with chemo
Food and Drug Administration has expanded the indication for brentuximab vedotin - in combination with chemotherapy - to certain types of peripheral T-cell lymp
Early consolidation therapy with brentuximab vedotin after autologous stem cell transplant improved progression-free survival of patients with Hodgkin lymphoma.
Seattle Genetics Reports Data from Phase I Trial of ADCETRIS ® (Brentuximab Vedotin) in Front-line Mature T-Cell Lymphomas (MTCL) -100 Percent Objective Response Rate, Including 88 Percent Complete Remissions, in Newly Diagnosed MTCL Patients
The drug being tested in this study is called brentuximab vedotin. Brentuximab vedotin is being tested to treat pediatric participants who have advanced stage, newly diagnosed, classical CD30+ HL. This study will assess the safety, tolerability, and anti-tumor activity, as well as recommended dose of brentuximab vedotin in combination with a multiagent chemotherapy regimen that is based on a current standard of care (SOC) first-line treatment regimen for newly diagnosed HL. The study will enroll approximately 55 evaluable participants. The study will be conducted in 2 phases, Phase 1 and Phase 2. Phase 1 study will enroll up to 12 participants to determine the recommended dose. Once the recommended dose is identified additional participants will be enrolled into phase 2 so that the total number of evaluable participants will be approximately 55, including participants treated at recommended dose in Phase 1. Participants will be enrolled in the following 2 dose Cohorts: • Brentuximab vedotin 48 ...
This study is investigating the tolerability of brentuximab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone in patients with CD30 positive
Seattle Genetics Highlights Updated Progression-Free Survival and Overall Survival Data from ADCETRIS® (Brentuximab Vedotin) Frontline PTCL Phase 1 Clinical Trial at the ESMO 2014 Congress
This is a Phase 1/2 multicenter study to assess the safety and effectiveness of brentuximab vedotin and bendamustine, when given together, in patients with
Common AEs associated with brentuximab vedotin, such as peripheral neuropathy and neutropenia, are often manageable with modifications to dose and schedule.
Brentuximab Vedotin can cause side effects such as fatigue, rash and itch, diarrhoea or constipation. Inform your doctor if you experience severe abdominal pain and shortness of breath.
Brentuximab Vedotin can cause side effects such as fatigue, rash and itch, diarrhoea or constipation. Inform your doctor if you experience severe abdominal pain and shortness of breath.
T cell-derived malignant lymphoma is rarely detected as a bladder neoplasm. A literature review for anaplastic large cell lymphoma (ALCL) involving urinary bladder reveals only seven previously reported cases. Here, we report a case of a 59-year-old
The roles of aberrant expression of constitutively active ALK chimeric proteins in the pathogenesis of anaplastic large-cell lymphoma (ALCL) have been well defi
TY - JOUR. T1 - Recurrent MSCE116K mutations in ALK-negative anaplastic large cell lymphoma. AU - Luchtel, Rebecca A.. AU - Zimmermann, Michael T.. AU - Hu, Guangzhen. AU - Dasari, Surendra. AU - Jiang, Manli. AU - Oishi, Naoki. AU - Jacobs, Hailey K.. AU - Zeng, Yu. AU - Hundal, Tanya. AU - Rech, Karen L.. AU - Ketterling, Rhett P.. AU - Lee, Jeong Heon. AU - Eckloff, Bruce W.. AU - Yan, Huihuang. AU - Gaonkar, Krutika S.. AU - Tian, Shulan. AU - Ye, Zhenqing. AU - Kadin, Marshall E.. AU - Sidhu, Jagmohan. AU - Jiang, Liuyan. AU - Voss, Jesse. AU - Link, Brian K.. AU - Syrbu, Sergei I.. AU - Facchetti, Fabio. AU - Bennani, N. Nora. AU - Slager, Susan L.. AU - Ordog, Tamas. AU - Kocher, Jean Pierre. AU - Cerhan, James R.. AU - Ansell, Stephen M.. AU - Feldman, Andrew L.. PY - 2019/6/27. Y1 - 2019/6/27. N2 - Anaplastic large cell lymphomas (ALCLs) represent a relatively common group of T-cell non- Hodgkin lymphomas (T-NHLs) that are unified by similar pathologic features but demonstrate marked ...
Anaplastic large cell lymphoma arises in thymocytes and requires transient T cell receptor expression for thymic egress. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Although anaplastic large-cell lymphomas (ALCL) carrying anaplastic lymphoma kinase (ALK) have a relatively good prognosis, aggressive forms exist. We have identified a novel translocation, causing the fusion of the TRAF1 and ALK genes, in one patient who presented with a leukemic ALK+ ALCL (ALCL-11 …
SummaryAnaplastic lymphoma kinase (ALK), which belongs to the insulin receptor tyrosine kinase superfamily, plays an important role in nervous system development. Due to chromosomal translocations, point mutations, and gene amplification, constitutively activated ALK has been implicated in a variety of human cancers, including anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer, and ...
... including deparaffinization and antigen retrieval. For formalin-fixed paraffin-embedded tissues, antigen-retrieval is often ... CD15 and CD30 : used for Hodgkin's disease. Alpha fetoprotein: for yolk sac tumors and hepatocellular carcinoma. CD117 (KIT): ... "IHC Tip 1: Antigen retrieval - should I do PIER or HIER?". AbD Serotec. Archived from the original on 2016-04-23. Retrieved ... Visualising an antibody-antigen interaction can be accomplished in a number of ways, mainly either of the following: ...
It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL. The drug is ... The antibody cAC10 part of the drug binds to CD30 which often occurs on diseased cells but rarely on normal tissues. The ... This approval is for patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis ... August 2003). "cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity". ...
Typically, one of the Fabs binds to a tumour antigen (such as CD30) and the other to a protein on the surface of an immune cell ... Two chemically linked fragments antigen-binding form an artificial antibody that binds to two different antigens, making it a ... They are fragments antigen-binding (Fab or Fab') of two different monoclonal antibodies and are linked by chemical means like a ... antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen- ...
Unlike classic RSC, the non-classic popcorn-shaped RS cells of NLPHL are CD15 and CD30 negative while positive for the B cell ... and CD79a and also express the common leukocyte antigen CD45, which is uncommon on RSH cells. The LP cells have scant cytoplasm ... RSH cells typically express CD15 and CD30, whereas LP cells lack expression of these markers, but express B cell markers like ...
... forssman antigen MeSH D23.050.285.018 - antigens, cd24 MeSH D23.050.285.025 - antigens, cd30 MeSH D23.050.285.040 - antigens, ... antigens, cd28 MeSH D23.050.301.264.035.129 - antigens, cd29 MeSH D23.050.301.264.035.130 - antigens, cd30 MeSH D23.050.301.264 ... antigens, cd28 MeSH D23. - antigens, cd29 MeSH D23. - antigens, cd30 MeSH D23. - ... antigens, thy-1 MeSH D23.101.840.050 - alpha-fetoproteins MeSH D23.101.840.055 - antigens, cd30 MeSH D23.101.840.075 - antigens ...
... chimeric antigen receptor T cells that have been modified to target and destroy cells bearing CD30. A phase 1 study sponsored ... the drug binds to the cell-membrane protein CD30 to deliver thereby the antimitotic aged into CD30-bearing target cells. This ... At these sites, IEL are exposed and regulate immune responses to non-dietary and dietary antigens, pathogenic and non- ... A phase 1 study sponsored by the National Institutes of Health Clinical Center is recruiting patients that have CD30-expressing ...
... +Antigens at the US National Library of Medicine Medical Subject Headings (MeSH) Human TNFRSF8 genome location and TNFRSF8 ... Various types of CD30-positive B cell lymphomas Various types of CD30-positive T cell lymphomas CD30-positive cases of the NK ... Josimovic-Alasevic O, Dürkop H, Schwarting R, Backé E, Stein H, Diamantstein T (Jan 1989). "Ki-1 (CD30) antigen is released by ... CD30 and CD15 are also expressed on Reed-Sternberg cells typical for Hodgkin's lymphoma. CD30 is the target of the FDA approved ...
There are also efforts underway to engineer CARs targeting many other blood cancer antigens, including CD30 in refractory ... Identification of good antigens has been challenging: such antigens must be highly expressed on the majority of cancer cells, ... After an antigen is bound to the external antigen recognition domain, CAR receptors cluster together and transmit an activation ... T cells are genetically engineered to express chimeric antigen receptors specifically directed toward antigens on a patient's ...
This antigen along with other blood group antigens was used to identify the Basque people as a genetically separate group.[49] ... Because the Duffy antigen is uncommon in those of Black African descent, the presence of this antigen has been used to detect ... The Fy4 antigen, originally described on Fy (a-b-) RBCs, is now thought to be a distinct, unrelated antigen and is no longer ... The Duffy antigen is expressed in greater quantities on reticulocytes than on mature erythrocytes.[21] While the Duffy antigen ...
The Vδ2+ T cells recognize small non-peptide antigens, but unlike αβ T cells, these antigens do not need to be processed by ... Gammon B, Gammon BR, Kim YH, Kim J (September 2016). "Neurotropic Gamma-Delta T-Cell Lymphoma With CD30-Positive Lymphoid ... While the αβ lineage has been widely studied, the γδ lineage has not due to the minimal number of defined antigens, the unusual ... There is a hypothesis that γδ T cells process these pathogenic antigens, transport them to draining lymph nodes, and then ...
Yaakup H, Sagap I, Fadilah SA (October 2008). "Primary oesophageal Ki (CD30)-positive ALK+ anaplastic large cell lymphoma of T- ... March 2002). "ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes". ... CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin". Cancer Research. 62 (5): 1559-66. PMID ...
Sialyl Lewis X is also one of the most important blood group antigens and is displayed on the terminus of glycolipids that are ... Immunohistochemical panels for the diagnosis of Hodgkins disease typically employ CD15 along with CD30 and CD45; the latter ... Sialyl Lewis x is also an inflammation-associated antigen on liver cells. It becomes over expressed on diseased liver cells and ... Sialyl LewisX (sLeX) also known as cluster of differentiation 15s (CD15s) or stage-specific embryonic antigen 1 (SSEA-1), is a ...
This agent is a CD30-targeting antibody that delivers a toxin, monomethyl auristatin E, to CD30-expressing cells, has ... Zheng XH, Zhang XY, Dong QQ, Chen F, Yang SB, Li WB (January 2020). "Efficacy and safety of chimeric antigen receptor-T cells ... As indicated in the following Treatments and prognoses section, expression of the CD20 and CD30 proteins as well as the CD19, ... Monoclonal antibodies directed against CD19, CD22, CD30, and PD-L1 have been developed for use as immunotherapeutic agents in ...
Target antigen detection methods[edit]. The direct method is a one-step staining method and involves a labeled antibody (e.g. ... CD15 and CD30 : used for Hodgkin's disease. *Alpha fetoprotein: for yolk sac tumors and hepatocellular carcinoma ... including deparaffinization and antigen retrieval. For formalin-fixed paraffin-embedded tissues, antigen-retrieval is often ... Prostate specific antigen (PSA): for prostate cancer. *estrogens and progesterone receptor (ER & PR) staining are used both ...
CK19, Cytokeratin 19, K19) Kit L-selectin (CD62L) Lamin A/C Lewis X antigen (Le(X)) LeX Lgr5 Lrp4 MCM2 MCSP Metallothionein (MT ... CD30) PECAM-1 (CD31) Siglec-3 (CD33) CD34 CD44 NCAM (CD56) CD73 CD9 CD90 CDCP1 Circulating anticoagulants protein C (PC) CK19 ... May 2006). "Lack of expression of the chondroitin sulphate proteoglycan neuron-glial antigen 2 on candidate stem cell ... Muramatsu T, Muramatsu H (2004). "Carbohydrate antigens expressed on stem cells and early embryonic cells". Glycoconjugate ...
The cells usually do not express CD5, CD10, CD30, or CD138. The neoplastic cells are also usually characterized as being of the ... chimeric antigen receptor T cell therapy using CD19-directed CAR-T cells; and lenalidomide, a drug with multiple anti-tumor ...
... as well as activation and plasma cell marker proteins such as CD30, MUC1, CD38, syndecan 1, and IRF4/MUM1; they do not express ... or one of the various tests for hepatitis C antigen. Extracavitary PEL is diagnosed based on findings that their mass lesions ... the malignant cells in Type II PEL frequently express CD20 but often do not express CD30) and gene abnormalities (e.g. the ... with PEL that is associated with cirrosis due to hepatitis evidence positive serum tests for the hepatitis virus B antigen ( ...
A new ligand for human leukocyte antigen class II antigens". The Journal of Experimental Medicine. 176 (2): 327-37. doi:10.1084 ... "Soluble CD30 and lymphocyte activation gene-3 (CD223), as potential serological markers of T helper-type cytokine response ... A new ligand for human leukocyte antigen class II antigens". The Journal of Experimental Medicine. 176 (2): 327-37. doi:10.1084 ... antigen processing and presentation of exogenous peptide antigen via MHC class II. ...
... antigens, cd27 MeSH D12.776.543.750.705.852.760.072 - antigens, cd30 MeSH D12.776.543.750.705.852.760.097 - antigens, cd40 MeSH ... antigen, b-cell MeSH D12.776.543.750.705.816.821.500 - antigens, cd79 MeSH D12.776.543.750.705.816.824 - receptors, antigen, t- ... antigens, cd22 MeSH D12.776.543.550.200.124 - antigens, cd24 MeSH D12.776.543.550.200.131 - antigens, cd31 MeSH D12.776.543.550 ... antigens, cd11a MeSH D12.776.543.750.705.408.100.150 - antigens, cd11b MeSH D12.776.543.750.705.408.100.200 - antigens, cd11c ...
T cells that produce IL-12 have a coreceptor, CD30, which is associated with IL-12 activity. IL-12 plays an important role in ... Zheng, Hua; Ban, Yi; Wei, Fang; Ma, Xiaojing (2016), Ma, Xiaojing (ed.), "Regulation of Interleukin-12 Production in Antigen- ... Interleukin 12 (IL-12) is produced by activated antigen-presenting cells (dendritic cells, macrophages). It promotes the ...
antigen processing and presentation of exogenous peptide antigen via MHC class II. • proteolysis. • neutrophil degranulation. ... brain antigen processing and regulation of programmed cell death.[17][18][19][20] ... CD30. Prostate cancer. *Prostate-specific antigen. *Prostatic acid phosphatase. *Glutamate carboxypeptidase II ...
CD30. Prostate cancer. *Prostate-specific antigen. *Prostatic acid phosphatase. *Glutamate carboxypeptidase II ...
An anticancer drug is coupled to an antibody that specifically targets a certain tumor antigen (e.g. a protein that, ideally, ... However, MMAE linked to an anti-CD30 monoclonal antibody (cAC10, a cell membrane protein of the tumor necrosis factor or TNF ... The biochemical reaction between the antibody and the target protein (antigen) triggers a signal in the tumor cell, which then ... to human-specific CD30-positive malignant cells. MMAE inhibits cell division by blocking the polymerization of tubulin. Because ...
CD30. rak prostate. *prostatični specifični antigen. *prostatična kisla fosfataza. *glutamat karboksipeptaza II ...
CAR-T treatment has significant side effects, and loss of the antigen targeted by the CAR-T cells is a common mechanism for ... CD (30 July 2009). "The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute ... One such approach used genetically modified T cells, known as chimeric antigen receptor T cells (CAR-T cells), to attack cancer ...
Ebert LM, McColl SR (2002). "Up-regulation of CCR5 and CCR6 on distinct subpopulations of antigen-activated CD4+ T lymphocytes ... This receptor has been shown to be important for B-lineage maturation and antigen-driven B-cell differentiation, and it may ... dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens". J. Immunol. 167 (11): ...
... or CD30; and, in particular, by their overexpression of megakaryocyte-associated tyrosine kinase. They are not infected with ... and T-cell intracellular antigen-1) but no genetic abnormalities. Indolent T cell lymphoproliferative disorder of the ... by its T cells that express CD30 but not CD56 or megakaryocyte-associated tyrosine kinase. and by most (95%) individuals with ...
It is also called Lewis x and SSEA-1 (stage-specific embryonic antigen 1) and represents a marker for murine pluripotent stem ... Immunohistochemical panels for the diagnosis of Hodgkins disease typically employ CD15 along with CD30 and CD45; the latter ... CD15 Antigen at the US National Library of Medicine Medical Subject Headings (MeSH) ... CD15 (3-fucosyl-N-acetyl-lactosamine) is a cluster of differentiation antigen - an immunologically significant molecule. CD15 ...
It increases MHC II and adhesion molecules LFA-1 and LFA-3 (lymphocyte function-associated antigen). ...
CD30 • CD31 • CD32 (A, B) • CD33 • CD34 • CD35 • CD36 • CD37 • CD38 • CD39 • CD40 • CD41 • CD42 (a, b, c, d) • CD43 • CD44 • ... 2000). "Characterization of a new member of the TNF family expressed on antigen presenting cells.". Biol. Chem. 380 (12): 1443- ... "BLyS receptor signatures resolve homeostatically independent compartments among naïve and antigen-experienced B cells.". Semin ...
Macrophage-1 antigen (CD11b+CD18). *VLA-4 (CD49d+CD29). *Glycoprotein IIb/IIIa (ITGA2B+ITGB3) ...
Seligman P. A., Butler C. D., Massey E. J., etal. The p97 antigen is mapped to the q24-qter region of chromosome 3; the same ... Le Beau M. M., Diaz M. O., Plowman G. D., etal. Chromosomal sublocalization of the human p97 melanoma antigen. (англ.) // Hum. ... Plowman G. D., Brown J. P., Enns C. A., etal. Assignment of the gene for human melanoma-associated antigen p97 to chromosome 3 ... Rose T. M., Plowman G. D., Teplow D. B., etal. Primary structure of the human melanoma-associated antigen p97 ( ...
The antibody will be targeted at a preferentially expressed protein in the tumour cells (known as a tumor antigen) or on cells ... They bind to the tumor antigen and are internalised, where the linker releases the drug into the cell. These specially targeted ...
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) also known as CD66e (Cluster of Differentiation 66e), is a ... 2001). "Heterogeneous RNA-binding protein M4 is a receptor for carcinoembryonic antigen in Kupffer cells". J. Biol. Chem. 276 ( ... CEACAM5, CD66e, CEA, carcinoembryonic antigen related cell adhesion molecule 5. External IDs. HomoloGene: 128801 GeneCards: ... Oikawa S, Nakazato H, Kosaki G (1987). "Primary structure of human carcinoembryonic antigen (CEA) deduced from cDNA sequence". ...
The protein also carries the Jr(a) antigen, which defines the Junior blood group system.[9] ...
van Rhenen A., van Dongen G. A., Kelder A., et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination ...
"Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin". Molecular and ...
CD30 • CD31 • CD32 (A, B) • CD33 • CD34 • CD35 • CD36 • CD37 • CD38 • CD39 • CD40 • CD41 • CD42 (a, b, c, d) • CD43 • CD44 • ... CD97 antigen je protein koji je kod ljudi kodiran CD97 genom.[1][2][3] ... 2001). "Tissue distribution of the human CD97 EGF-TM7 receptor". Tissue Antigens 57 (4): 325-31. PMID 11380941. doi:10.1034/j. ... "Expression cloning and chromosomal mapping of the leukocyte activation antigen CD97, a new seven-span transmembrane molecule of ...
Autoreactive thymic B cells are efficient antigen-presenting cells of cognate self-antigens for T cell negative selection., 110 ... CD3 (diferentseerumise marker 3); CD4, CD8, CD30, CD120 (TNFR), CD150, CD152, CD279. ... Ana C. Anderson ja Vijay K. Kuchroo, Expression of Self-antigen in the Thymus A Little Goes a Long Way, 1. detsember 2003 // ... Christian Koble ja Bruno Kyewski, The thymic medulla: a unique microenvironment for intercellular self-antigen transfer, J. Exp ...
"Entrez Gene: ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)".. *^ May, K. E.; Villar, J.; Kirtley, S.; ... CD61+Antigens at the US National Library of Medicine Medical Subject Headings (MeSH) ...
The Reed-Sternberg cells are identified as large often bi-nucleated cells with prominent nucleoli and an unusual CD45-, CD30+, ... is not routinely used to treat Hodgkin lymphoma due to the lack of CD20 surface antigens in most cases. The use of rituximab in ...
"Direct association of adenosine deaminase with a T cell activation antigen, CD26". Science. 261 (5120): 466-9. doi:10.1126/ ...
B cells can present antigens to a specialized group of helper T cells called TFH cells. If an activated TFH cell recognizes the ... Roles of T cell-B-cell-activating molecule (5c8 antigen) and CD40 in contact-dependent help". Journal of Immunology. 149 (12): ... It binds to CD40 (protein) on antigen-presenting cells (APC), which leads to many effects depending on the target cell type. In ... Grewal, IS; Xu, J; Flavell, RA (7 December 1995). "Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand". ...
antigen processing and presentation of peptide antigen via MHC class I. • antigen processing and presentation of exogenous ... antigen processing and presentation of exogenous peptide antigen via MHC class I. • lipoprotein transport. • negative ... peptide antigen via MHC class I, TAP-dependent. • platelet degranulation. • MyD88-dependent toll-like receptor signaling ...
Primarily, the VCAM-1 protein is an endothelial ligand for VLA-4 (Very Late Antigen-4 or integrin α4β1) of the β1 subfamily of ...
... uveitis antigens induce CXCR3- and CXCR5-expressing lymphocytes and immature dendritic cells to migrate (англ.) // Blood (англ ...
In addition to aiding with cytotoxic T cell antigen interactions the CD8 co-receptor also plays a role in T cell signaling. The ... the CD8 co-receptor plays a role in T cell signaling and aiding with cytotoxic T cell antigen interactions. ... This affinity keeps the T cell receptor of the cytotoxic T cell and the target cell bound closely together during antigen- ... Once the T cell receptor binds its specific antigen Lck phosphorylates the cytoplasmic CD3 and ζ-chains of the TCR complex ...
Because the keratin-7 antigen is found in both healthy and neoplastic cells, antibodies to CK7 can be used in ... CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin". Cancer Research. 62 (5): 1559-66. PMID ...
antigen binding. • virus receptor activity. • protein binding. • transmembrane signaling receptor activity. • identical protein ...
CD30 • CD31 • CD32 (A, B) • CD33 • CD34 • CD35 • CD36 • CD37 • CD38 • CD39 • CD40 • CD41 • CD42 (a, b, c, d) • CD43 • CD44 • ... 1996). "CD88 antibodies specifically bind to C5aR on dermal CD117+ and CD14+ cells and react with a desmosomal antigen in human ...
CD74 (англ. HLA class II histocompatibility antigen gamma chain; HLA-DR antigens-associated invariant chain) - мембранный белок ... II histocompatibility antigen gamma chaingamma chain of class II antigensIiHLA-DR antigens-associated invariant chainIa antigen ... Riberdy J.M., Newcomb J.R., Surman M.J., Barbosa J.A., Cresswell P. HLA-DR molecules from an antigen-processing mutant cell ... Machamer C.E., Cresswell P. Biosynthesis and glycosylation of the invariant chain associated with HLA-DR antigens (англ.) // ...
Targeting CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment ... for CD30. No chemotherapy was given to patients immediately before or after infusion of CD30.CAR-transduced T cells (CD30.CAR- ... Soluble CD30 (sCD30) is typically elevated in advanced HL (30). Although CD30.CAR-Ts are not blocked by sCD30 (26, 31), we ... In our study, CD30.CAR-Ts were well tolerated, and CRs were observed at the highest dose of CD30.CAR-Ts and after 2 or more T ...
Downloading a figure as powerpoint requires a browser with javascript support. Enable javascript and try again For help please contact [email protected] ...
CD30 is expressed only in a small population of activated lymphoid blasts. Since then, several reports have be … ... expression of the CD30 antigen was shown to be typical of the tumour cells of Hodgkins disease (HD) and of anaplastic large ... Expression of the CD30 antigen in non-lymphoid tissues and cells J Pathol. 2000 Apr;190(5):613-8. doi: 10.1002/(SICI)1096-9896( ... Originally, expression of the CD30 antigen was shown to be typical of the tumour cells of Hodgkins disease (HD) and of ...
The invention describes a CAR which recognizes CD30 as a target antigen and initiates lysis of CD30-positive (CD30+) tumor ... Anti CD30 CAR - Anti CD30 chimeric antigen receptor selectively targets tumor cells. 02.09.2015 ... In vivo experiments provided evidence that the treatment with anti-CD30 T-cells has no unwanted impact on the endogenous immune ... Specific genetic modifications of the anti-CD30 CAR ensure the specific targeting of CD30+ tumor cells and prevent unwanted ...
CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas (CART30). The ...
C) Killing of CD30+ (HDLM-2, ; Karpas, ■) and CD30− (□) tumor cells by CAR-CD30+ and CCR4+CD30-CAR+ T cells. (D) The ... Furthermore, T lymphocytes expressing both CCR4 and a chimeric antigen receptor directed to the HL associated antigen CD30 ... Improved migration of activated T lymphocytes genetically modified to overexpress CCR4 and a CAR targeting the CD30 antigen ... C) The fold change of bioluminescence signal between K/wt and K/TARC site for CAR-CD30+ (□) and CCR4+CAR-CD30+ (■) T cells. ...
Overexpression of CD30 antigen in hematopoietic malignancies make the antigen clinically useful as a biological tumor marker. ... CD30" by people in this website by year, and whether "Antigens, CD30" was a major or minor topic of these publications. ... "Antigens, CD30" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical Subject ... Below are the most recent publications written about "Antigens, CD30" by people in Profiles. ...
... Clone: Ber-H2 Isotype: IgG1 Kappa This monoclonal antibody detects the CD30 antigen, a 105 kD transmembrane ...
Antigen, Cd30 Antigen, Hodgkins Lymphoma, Lymphoma, Chemotherapy, History, Hodgkin Lymphoma, Natural History, Apoptosis, Cell, ... Expression of CD30 in patients with acute graft-versus-host disease. < .001. There were similar levels of CD30 expression in ... CD30 ligand/CD30 plays a critical role in Th17 differentiation in mice. Abstract ... These results suggest that CD30 expression on CD8(+) T-cell subsets or plasma levels of soluble CD30 may be a potential ...
Antigens, CD30. Lymphoma. monomethylauristatin E. Drug Therapy. CD30-expression. PTCL. Additional relevant MeSH terms:. Layout ... A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL). The safety and ... Unsuitable or unfit for initial conventional combination chemotherapy for HL (Part E) or CD30-expressing PTCL due to the ... Treatment-naive patients with CD30-expressing PTCL (Part F). *Ineligible for or have declined initial conventional combination ...
Targeting CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment ... CD30.CAR-T expansion in peripheral blood peaked 1 week after infusion, and CD30.CAR-Ts remained detectable for over 6 weeks. ... Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. ... Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. ...
Human Monoclonal Antibody Shop CD30/TNFRSF8 Human anti-Human, Biotin, Clone: Hu8, R&D Systems™ ... CD30/TNFRSF8 Human anti-Human, Biotin, Clone: Hu8, R&D Systems™- ... CD30, CD30 antigen, CD30KI-1, CD30L receptor, cytokine receptor CD30, D1S166EKi-1, Ki-1 antigen, Lymphocyte activation antigen ... Detects human CD30/TNFRSF8 in direct ELISAs. This non-therapeutic antibody uses the same variable region sequence as the ...
Novus Biologicals CD30/TNFRSF8 Antibody; Alexa Fluor 532; 0.1 mL ... CD30/TNFRSF8 Mouse anti-Human, Alexa Fluor 532, Clone: rKi-1/ ... CD30, CD30 antigen, CD30KI-1, CD30L receptor, cytokine receptor CD30, D1S166EKi-1, Ki-1 antigen, Lymphocyte activation antigen ... CD30/TNFRSF8 Monoclonal antibody specifically detects CD30/TNFRSF8 in Human samples. It is validated for Flow Cytometry, ... CD30/TNFRSF8 Mouse anti-Human, Alexa Fluor 532, Clone: rKi-1/779, Novus Biologicals ...
Soluble CD30 (sCD30) is a suggested marker for kidney transplantation outcomes. We investigated whether sCD30 serum levels are ... Overexpression of CD30 antigen in hematopoietic malignancies make the antigen clinically useful as a biological tumor marker. ... Antigens, Cd30. A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B ... Summary of "Influence of immunosuppressive drugs on the CD30 molecule in kidney transplanted patients.". Soluble CD30 (sCD30) ...
... vedotin induced durable objective responses and resulted in tumor regression for most patients with relapsed or refractory CD30 ... Previous attempts to target the CD30 antigen with monoclonal-based therapies have shown minimal activity. To enhance the ... Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas N Engl J Med. 2010 Nov 4;363(19):1812-21. doi: 10.1056/ ... Background: Hodgkins lymphoma and anaplastic large-cell lymphoma are the two most common tumors expressing CD30. ...
Antigens, CD30. Antibody-Drug Conjugate. Antibodies, Monoclonal. Disease, Hodgkin. Drug Therapy. Hematologic Diseases. ...
Antigens, CD30. Drug Therapy. Hematologic Diseases. Immunotherapy. Monomethylauristatin E. Additional relevant MeSH terms: ... CD30-positive hematologic malignancy.. *At a minimum, experienced clinical benefit in the prior brentuximab vedotin study. For ... Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 ... Retreatment arm: Patients with CD30-positive hematologic malignancies who experienced a complete remission (CR) or partial ...
Recombinant Human CD30 protein (Fc Chimera) is a HEK 293 Protein fragment 19 to 379 aa range, , 95% purity, , 1.000 Eu/µg ... KI 1 antigen. *Ki-1 antigen. *KI1. *Lymphocyte activation antigen CD30. *TNFRSF 8 ... Recombinant Human CD30 protein (Fc Chimera). See all CD30 proteins and peptides. ... Immobilized Human CD30 Ligand, Mouse IgG2a Fc Tag, at 2 μg/mL (100 μL/well) can bind ab220597 with a linear range of 0.5-31 ng/ ...
Antigen Expression CD30 +; CD45 +; EMA + (epithelial membrane antigen). Comments The cells contain two viral genomes: Epstein- ... CD30 (Ki-1) positive anaplastic large cell lymphomas in individuals infected with the human immunodeficiency virus. Cancer 72: ... CD30 (Ki-1) positive anaplastic large cell lymphomas in individuals infected with the human immunodeficiency virus. Cancer 72: ...
Antigen Expression CD30 +; CD38 +; CD45 +; CD 54 +; CD71 +; HLA-DR +; EMA + (epithelial membrane antigen); CD2 -; CD3 -; CD4 ... The cells do not express B-cell lineage restricted antigens or kappa or lambda immunoglobulin light chains or T-cell lineage- ...
CD30 antigen, a marker for Hodgkins lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology ... CD30 antigen, a marker for Hodgkins lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology ... Sequence homology to members of the tumor necrosis factor (TNF) receptor super family can be observed in CD30, which is a ... cognate from the murine T cell clone 7B9 was expression cloned by using a chimeric probe with the extracellular region of CD30 ...
T1 - CD30 is a CD40-inducible molecule that negatively regulates CD40- mediated immunoglobulin class switching in non-antigen- ... CD30 is a CD40-inducible molecule that negatively regulates CD40- mediated immunoglobulin class switching in non-antigen- ... CD30 is a CD40-inducible molecule that negatively regulates CD40- mediated immunoglobulin class switching in non-antigen- ... CD30 is a CD40-inducible molecule that negatively regulates CD40- mediated immunoglobulin class switching in non-antigen- ...
CD30/412) [Alexa Fluor® 594]. Hodgkin & Reed-Sternberg Cell Marker. Validated: ELISA, Flow, ICC/IF, IHC, IHC-Fr, IHC-P. Tested ... Alternate Names for CD30/TNFRSF8 Antibody (CD30/412) [Alexa Fluor® 594]. *CD30 antigen ... Home » CD30/TNFRSF8 » CD30/TNFRSF8 Antibodies » CD30/TNFRSF8 Antibody (CD30/412) [Alexa Fluor® 594] ... CD30/TNFRSF8 Antibody (CD30/412) [Alexa Fluor® 594] Summary. Immunogen. A recombinant protein fragment specific to CD30 was ...
Human CD30 / TNFRSF8 protein (6126-CD) is manufactured by R&D Systems, over 95% purity. Reproducible results in bioactivity ... CD30 antigen; CD30; CD30KI-1; CD30L receptor; cytokine receptor CD30; D1S166EKi-1; Ki-1 antigen; Lymphocyte activation antigen ... Background: CD30/TNFRSF8. CD30, also known as Ki-1 antigen and TNFRSF8, is a 120 kDa type I transmembrane glycoprotein ... Soluble CD30 retains the ability to bind CD30 Ligand and functions as an inhibitor of normal CD30 signaling (15). ...
Antigens CD30. Biomarkers. Classification. Diffuse large B-cell lymphoma. Immunohistochemistry. Prognosis. Proto-oncogene ... A expressão do CD30 mostrou tendência a melhor prognóstico, porém a expressão de BCL2 e MYC avaliados isoladamente não ... Antígenos CD30. Biomarcadores. Classificação. Imuno-histoquímica. Linfoma difuso de grandes células B. Prognóstico. Proteínas ... The prognostic power of BCL2, CD30 and MYC expression were also assessed by IHC. RESULTS: None of the profiles assessed by IHC ...
Altered expression of the lymphocyte activation antigen CD30 in active celiac disease. (PMID: 20166880) Periolo N … Cherñavsky ... Suggested Antigen Peptide Sequences for TNFRSF8 Gene. GenScript: Design optimal peptide antigens:. *TNFRSF8 protein (A5D8T4_ ... Association study between CD30 and CD30 ligand genes and type 1 diabetes in the Japanese population. (PMID: 11960307) Ahmed S ... tumor necrosis factor receptor superfamily,member 8,cell differentiation antigen CD30 (Ki-1),lymphoid activating,identified by ...
Antigens, CD30 / blood*. Cyclosporine / adverse effects*, therapeutic use. Etretinate / therapeutic use. Fatal Outcome. Female ... 0/Antigens, CD30; 0/Immunosuppressive Agents; 0/Keratolytic Agents; 0/Tumor Markers, Biological; 54350-48-0/Etretinate; 59865- ...
Targeted Antigens Opportunities and Forecast to 2028 PR Newswire PUNE, India, August 3, 2018 PUNE, ... ... Targeted Antigens - Global CAR T Cell Therapy Market & Forecast: CD19, CD20, GD2, CD22, CD30, CD33, HER2, MESO, EGFRvII ... Targeted Antigens (CD19, CD20, GD2, CD22, CD30, CD33, HER2, MESO, EGFRvII, Others) Clinical Trials/Study (CD19, CD20, GD2, CD22 ... Global - CAR T Cell Therapy Clinical Trials/Study: CD19, CD20, GD2, CD22, CD30, CD33, HER1, HER2, EGFRvII MESO ...
Josimovic-Alasevic O, Dürkop H, Schwarting R, Backé E, Stein H, Diamantstein T (Jan 1989). "Ki-1 (CD30) antigen is released by ... Various types of CD30-positive T cell lymphomas[11]. *CD30-positive cases of the NK cell lymphoma, extranodal NK/T-cell ... CD30+Antigens at the US National Library of Medicine Medical Subject Headings (MeSH) ... Granados S, Hwang ST (Jun 2004). "Roles for CD30 in the biology and treatment of CD30 lymphoproliferative diseases". The ...
... and CD30 antigen (von Tresckow et al., 2004). By comparing two cell lines exhibiting different levels of cholesterol ( ... 2004). Depletion of cellular cholesterol and lipid rafts increases shedding of CD30. J. Immunol. 172, 4324-4331. doi: 10.4049/ ...
  • T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. (
  • Furthermore, T lymphocytes expressing both CCR4 and a chimeric antigen receptor directed to the HL associated antigen CD30 sustain their cytotoxic function and cytokine secretion in vitro, and produce enhanced tumor control when infused intravenously in mice engrafted with human HL. (
  • Targeting CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment antitumor activity. (
  • Sequence homology to members of the tumor necrosis factor (TNF) receptor super family can be observed in CD30, which is a surface marker for neoplastic cells of Hodgkin's lymphoma. (
  • Expression of CD30 by these cells is induced by CD40L but is inhibited by B cell receptor coengagement and/or exposure to IL-6 and IL-12. (
  • CD30, also known as Ki-1 antigen and TNFRSF8, is a 120 kDa type I transmembrane glycoprotein belonging to the TNF receptor superfamily (1, 2). (
  • CD30 , also known as TNFRSF8 , is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker . (
  • Clone mCD30.1 recognizes mouse CD30, a 105 kDa type I transmembrane glycoprotein, also known as tumor necrosis factor receptor superfamily member 8 (TNFRSF8). (
  • The CD30 antibody recognizes the human CD30 antigen, a member of the tumor necrosis factor receptor (TNFR) superfamily also known as the Ki-1, which is found on Hodgkin/Reed-Sternberg (H/RS) cells as well as on activated T and B lymphocytes. (
  • Activation of CD30, CD40, and receptor activator of nuclear kappaβ (RANK) receptors in HD cells by their respective ligands increased ERK phosphorylation above the basal level and promoted HD cell survival. (
  • CD30 is a member of the TNF receptor superfamily. (
  • Overexpression of CD30 on some neoplasms versus limited expression on normal tissues makes this receptor a promising target for antibody-based therapy. (
  • CD30 is a member of the TNF receptor superfamily, which includes TNF-R1, TNF-R2, Fas-R, CD40, CD27, and TNF-related apoptosis-inducing ligand receptor ( 1 ). (
  • This special receptor is known as Chimeric Antigen Receptor (CAR) that binds to specific protein on patient's cancer cells. (
  • A detailed summary of the published clinical trials of chimeric antigen receptor T cells (CAR-T) and TCR-transduced T cells (TCR-T) was constructed to understand the development trend of adoptive T cell therapy (ACT). (
  • The adoptive T cell therapy (ACT) is that T cells are genetically modified to express a chimeric antigen receptor (CAR) or T-cell receptor (TCR) has obtained impressive results in treating multiple types of tumors, such as hematologic malignancies, sarcoma and melanoma, etc. (
  • With long impending clinical trials and research activities carried out using chimeric antigen receptor cells (CAR-T) cells, these players in the pharmaceuticals industry are expected to launch various products in 2017 and commercialize them in the following two to three years. (
  • Zurück zum Zitat Wohlfarth P, Worel N, Hopfinger G. Chimeric antigen receptor Tcell therapy-a hematological success story. (
  • Axicabtagene Ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T‑cell therapy for relapsed/refractory large B‑cell Lymphoma: real world experience. (
  • The extracellular domain of CD30, comprising 365 residues, has proved to be homologous to that of the TNF-receptor superfamily. (
  • The CD30 gene is localized at chromosome 1q36, closely linked to other members of the TNF receptor superfamily comprising TNF-receptors, nerve growth factor, CD40, APO-1/Fas, CD27, OX40 and the neurotrophin receptor. (
  • Interactions of the cytokine receptor CD30 with its ligand induces pleiotropic biologic effects, such as differentiation, activation, proliferation and cell death. (
  • The vector of anti-CD30 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD30. (
  • CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells(APC). (
  • On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity. (
  • Gupta, Sorab 2018-05-04 00:00:00 Chimeric antigen receptor (CAR) T cell therapy is genetically engineered tumor antigen-specific anticancer immunotherapy, which after showing great success in hematological malignancies is currently being tried in advanced solid tumors like pancreatic cancer. (
  • CD30 is a type I transmembrane glycoprotein of the TNF receptor superfamily. (
  • In T cells, CD30 expression is present on a subset of T cells that produce Th2-type cytokines and on CD4+/CD8+ thymocytes that co-express CD45RO and the IL4 receptor. (
  • Immobilized Human CD30 Ligand, Mouse IgG2a Fc Tag, at 5 μg/mL (100 μL/well) can bind ab220597 with a linear range of 8-125 ng/mL. (
  • Measured by its ability to block CD30 Ligand-induced IL-6 secretion by HDLM human Hodgkin's lymphoma cells. (
  • The ED 50 for this effect is 1-5 μg/mL in the presence of 50 ng/mL of Recombinant Human CD30 Ligand (Catalog # 1028-CL). (
  • CD30 binds to CD30 Ligand/TNFSF8 which is expressed on activated Th cells, monocytes, granulocytes and medullary thymic epithelial cells (1, 5). (
  • Soluble CD30 retains the ability to bind CD30 Ligand and functions as an inhibitor of normal CD30 signaling (15). (
  • The ligand for CD30 is CD153. (
  • CD30 Ligand" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (
  • This graph shows the total number of publications written about "CD30 Ligand" by people in Harvard Catalyst Profiles by year, and whether "CD30 Ligand" was a major or minor topic of these publication. (
  • Below are the most recent publications written about "CD30 Ligand" by people in Profiles. (
  • Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines. (
  • Kennedy MK, Willis CR, Armitage RJ: Deciphering CD30 ligand biology and its role in humoral immunity. (
  • Fischer M, Harvima IT, Carvalho RF, Möller C, Naukkarinen A, Enblad G, Nilsson G: Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. (
  • This cytokine is a ligand for TNFRSF8/CD30, which is a cell surface antigen and a marker for Hodgkin lymphoma and related hematologic malignancies. (
  • It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. (
  • CD153 (CD30 ligand) has been described as a 40-kDa type II transmembrane glycoprotein belonging to the TNF superfamily and is expressed primarily by activated T cells, B cells and monocytes. (
  • Goldie-Cregan, LC, Croager, EJ & Abraham, L 2002, ' Characterization of the murine CD30 ligand (CD153) gene: Gene structure and expression ', Tissue Antigens , vol. 60, pp. 139-146. (
  • Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. (
  • Since the initial description of monoclonal antibodies against Hodgkin and Sternberg-Reed (HRS) cells in Hodgkin's lymphoma, 3 , 4 the CD30 antigen has attracted substantial scientific interest. (
  • A number of murine monoclonal antibodies against CD30, both in native form or linked to a variety of different toxins including ricin A-chain, radioisotopes or cytostatic drugs, were evaluated for their therapeutic effects in clinical trials of patients with Hodgkin's lymphoma. (
  • 13 In addition, human or humanized monoclonal antibodies against CD30 also gave disappointing clinical results. (
  • Anti-CD30 monoclonal antibodies have been investigated for the treatment of CD30-expressing malignancies in vitro and in vivo ( 10 , 12 - 18 ). (
  • Several studies have shown that anti-CD30 monoclonal antibodies possessing signaling properties could inhibit the growth of ALCL cells, but very few of them were effective for HD cells ( 10 , 12 , 13 , 18 ). (
  • Furthermore, although preclinical studies showed that treatment with anti-CD30 monoclonal antibodies prolonged the survival of ALCL-bearing mice significantly, compared with the mice in the control group, many of the mice in the treatment group still died of the disease ( 15 , 16 ). (
  • Monoclonal antibodies directed against tumor-associated antigens armed with diverse radionuclides are being investigated as therapeutic agents for the treatment of malignant disease ( 20 - 24 ). (
  • Examples are lymphoma antibodies hitting CD20, CD30, CD52. (
  • Those antibodies also kill the normal lymphocytes with those antigens, with the ill effects dependent on how important those normal ones are. (
  • It involves the process of selectively identifying antigens (proteins) in cells of a tissue section by exploiting the principle of antibodies binding specifically to antigens in biological tissues. (
  • Although antibodies show preferential avidity for specific epitopes, they may partially or weakly bind to sites on nonspecific proteins (also called reactive sites) that are similar to the cognate binding sites on the target antigen. (
  • Primary antibodies are raised against an antigen of interest and are typically unconjugated (unlabeled), while secondary antibodies are raised against immunoglobulins of the primary antibody species. (
  • The classical structure of CAR is built with a intracellular costimulatory domain, a intracellular CD3ζ and a chimera of single chain fragment (scFv) of antibodies that can directly target tumor associated antigens (TAA) in a major histocompatibility complex (MHC)-independent manner [ 4 ]. (
  • Recent clinical studies on several classes of experimental drugs, including small molecule inhibitors of protein kinases ( 14 - 16 ) and antibodies targeting vascular endothelial growth factor ( 17 ) or the RCC-associated antigen CAIX ( 18 ), have shown promise. (
  • One of the antibodies, LN53, recognizes an EQEQE repeat epitope in ORF73 and reacts with antigens in paraffin-embedded tissue ( 34 ). (
  • See our complete line of Immunohistochemistry Reagents including antigen retrieval solutions, blocking agents ABC Detection Kits and polymers, biotinylated secondary antibodies, substrates and more. (
  • Antibodies circulate throughout the body until they find and attach to the antigen. (
  • Researchers can design antibodies that specifically target a certain antigen, such as one found on cancer cells. (
  • Detects human CD30/TNFRSF8 in direct ELISAs. (
  • CD30/TNFRSF8 Monoclonal antibody specifically detects CD30/TNFRSF8 in Human samples. (
  • There are currently no images for CD30/TNFRSF8 Antibody (NBP2-33196AF594). (
  • rh CD30/TNFRSF8 (Catalog # 813-CD) is also available with a Fc and a His tag! (
  • Originally, expression of the CD30 antigen was shown to be typical of the tumour cells of Hodgkin's disease (HD) and of anaplastic large cell lymphomas (ALCLs). (
  • Brentuximab vedotin induced durable objective responses and resulted in tumor regression for most patients with relapsed or refractory CD30-positive lymphomas in this phase 1 study. (
  • CD30 (Ki-1) positive anaplastic large cell lymphomas in individuals infected with the human immunodeficiency virus. (
  • About one third of the Ki-1 positive lymphomas lack the leukocyte common antigen (CD45). (
  • CD30-positive malignant lymphomas: time for a change of management? (
  • describe CD30 expression in peripheral T-cell lymphomas. (
  • These data contribute to the growing body of evidence on a changing landscape in the treatment of CD30-positive malignant lymphomas. (
  • 5 , 6 Shortly thereafter, CD30 was also found on the malignant cells of anaplastic large cell lymphoma (ALCL) and other malignant lymphomas. (
  • Another paper published in this issue of the journal describes the molecular and phenotypic features common to CD30-positive peripheral T-cell lymphomas, and significant differences between CD30-negative and CD30-positive peripheral T-cell lymphomas, not otherwise specified, suggesting that CD30 expression might delineate two biologically distinct subgroups within this heterogeneous category. (
  • The putative clinical relevance of these subgroups could be the potential benefits of incorporating anti-CD30 immunoconjugates into the treatment strategies of CD30-positive peripheral T-cell lymphomas, not otherwise specified. (
  • In summary, radiolabeled HeFi-1 is very promising for the treatment of CD30-expressing leukemias and lymphomas, and the combination regimen of 211 At-HeFi-1 with unmodified HeFi-1 enhanced the therapeutic efficacy. (
  • An anti-CD52 ANTIGEN monoclonal antibody used for the treatment of certain types of CD52-positive lymphomas (e.g. (
  • Later, the Ki-1 antigen was found to be consistently expressed by a subgroup of diffuse largecell lymphomas that were called Ki-1 positive (Ki-1+) anaplastic large-cell lymphomas (ALCL). (
  • CD30 has a critical role in the pathophysiology of Hodgkin's disease and other CD30+ lymphomas. (
  • In addition to its expression on Hodgkin's and Reed-Sternberg cells, CD30 is also found in some non-Hodgkin's lymphomas (including Burkitt's lymphomas), virus-infected T and B cells, and on normal T and B cells after activation. (
  • Aims -To investigate whether MUC1 mucin, a high molecular weight transmembrane glycoprotein, also known as epithelial membrane antigen (EMA), differs in its expression and degree of glycosylation between anaplastic large cell lymphoma (ALCL) and classic Hodgkin's disease (HD), and whether MUC1 immunostaining can be used to differentiate between CD30 positive large cell lymphomas. (
  • Therefore, although MUC1 could be used in a panel of markers for CD30 positive lymphomas, it is probably not a valuable tool to differentiate between ALK negative CD30 positive large cell lymphomas. (
  • 7, 10, 12, 13 Morphologically, these lymphomas may closely resemble systemic ALCL, being also characterised by CD30 positive tumour cells with abundant cytoplasm, large irregular nuclei, and a prominent single nucleolus or multiple nucleoli. (
  • Several markers can be used in the differential diagnosis of ALCL and other CD30 positive lymphomas. (
  • The population to be studied includes treatment-naïve patients with classical Hodgkin lymphoma (HL) or treatment-naïve patients with CD30-expressing peripheral T-cell lymphoma (PTCL). (
  • CD30 immunohistochemistry (IHC) in malignant lymphoma is used for selection of patients in clinical trials using brentuximab vedotin, an antibody drug-conjugate targeting the CD30 molecule. (
  • Hodgkin's lymphoma and anaplastic large-cell lymphoma are the two most common tumors expressing CD30. (
  • In this phase 1, open-label, multicenter dose-escalation study, we administered brentuximab vedotin (at a dose of 0.1 to 3.6 mg per kilogram of body weight) every 3 weeks to 45 patients with relapsed or refractory CD30-positive hematologic cancers, primarily Hodgkin's lymphoma and anaplastic large-cell lymphoma. (
  • CD30 is associated with anaplastic large cell lymphoma . (
  • [6] CD30 and CD15 are also expressed on Reed-Sternberg cells typical for Hodgkin's lymphoma . (
  • Pearson JM, Borg-Grech A: Primary Ki-1 (CD30)-positive, large cell, anaplastic lymphoma of the esophagus. (
  • Ross CW, Hanson CA, Schnitzer B: CD30 (Ki-1)-positive, anaplastic large cell lymphoma mimicking gastrointestinal carcinoma. (
  • The CD30 antigen is known to be expressed on the Reed-Sternberg cells of HL and on sALCL, an aggressive type of T-cell non-Hodgkin lymphoma. (
  • Your doctor will get your lymphoma cells tested to see if they have certain markers -- proteins called antigens. (
  • You'll get a monoclonal antibody drug that aims at the antigens found on your lymphoma cells. (
  • This drug targets the CD20 antigen, which many types of lymphoma make too much of. (
  • You might get a monoclonal antibody that targets a different antigen that's found on your lymphoma cells. (
  • Your lymphoma cells might have the CD30 antigen, in which case brentuximab vedotin ( Adcetris ), a monoclonal antibody attached to chemo, might be part of your treatment plan. (
  • Brentuximab vedotin is a CD30-directed antibody-drug conjugate initially approved for the treatment of relapsed-refractory Hodgkin's lymphoma. (
  • describe their experience with the anti-CD30 antibody-drug conjugate brentuximab vedotin in patients with relapsed/refractory Hodgkin's lymphoma. (
  • Initially termed Ki-1, this antigen was clustered as CD30 showing a very strong expression on the malignant cells in Hodgkin's lymphoma. (
  • The CD30 antigen was subsequently also detected in mediastinal B-cell lymphoma, immunoblastic lymphoma, adult T-cell lymphoma and leukemias, mycosis fungoides, multiple myeloma, germinal center lymphoma, thyroid carcinoma and malignant mastocytosis. (
  • In addition, it could be demonstrated that CD30 is also present at a high density in patients with relapsed or refractory Hodgkin's lymphoma. (
  • brentuximab-vedotin, an ADC targeting CD30, is approved for the treatment of tumors arising from these cell populations, including Hodgkin lymphoma and systemic anaplastic large cell lymphoma ( 2, 5, 6 ). (
  • Polatuzumab vedotin targets CD79b, an antigen expressed in B cells and B-cell lymphoma ( 9 ). (
  • In this study, we evaluated the therapeutic efficacy of an anti-CD30 antibody, HeFi-1, armed with 211 At in a leukemia (karpas299) model and with 90 Y in a lymphoma (SUDHL-1) model. (
  • Increased expression of CD30 is observed on some neoplasms including Hodgkin's disease (HD), anaplastic large cell lymphoma (ALCL), mediastinal B cell lymphoma, embryonal carcinoma, seminoma, and mesothelioma ( 2 - 7 ). (
  • PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA (pcALCL) is an indolent CD30 + lymphoma usually treated with local therapy. (
  • ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, the defining marker of Hodgkin lymphoma. (
  • ADCETRIS was evaluated in two phase I trials for patients with CD30-positive hematologic malignancies, primarily Hodgkin lymphoma. (
  • Wright CW, Rumble JM, Duckett CS: CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells. (
  • In addition, tissue biopsy samples from 10 Hodgkin lymphoma and 5 ALCL patients who had relapsed or progressed after BV treatment were analyzed by immunohistocytochemistry for CD30 expression. (
  • The resistant ALCL cell line, but not the Hodgkin lymphoma cell line, demonstrated downregulated CD30 expression compared with the parental cell line. (
  • For both Hodgkin lymphoma and ALCL, samples from patients relapsed/resistant on BV persistently expressed CD30 by immunohistocytochemistry. (
  • Hodgkin lymphoma is characterized by the presence of Reed-Sternberg cells, which comprise only a minority of cells in the tumor mass and express CD30 surface antigen ( 6 ). (
  • Alternatively, ALCL is comprised of CD30-expressing lymphoma cells in the majority of the tumor mass. (
  • Anaplastic lymphoma of the skin which develops as a primary neoplasm expressing the CD30 ANTIGEN. (
  • It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL. (
  • This approval is for patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF). (
  • Pornkuna R, Takemoto S (2014) A Lack of Cellular Senescence, Formation of Microenvironment, and Role of Soluble Cd30 in Development of Adult T-Cell Leukemia/Lymphoma. (
  • CD30, the target of Adcetris, is the characteristic marker of classical Hodgkin lymphoma, anaplastic large-cell lymphoma, and embryonal-cell carcinoma. (
  • We have one ADC-brentuximab vedotin (Adcetris)-that's had a major impact in Hodgkin lymphoma and CD30-positive non-Hodgkin lymphoma. (
  • Further data for brentuximab vedotin are also expected in 2018 as front-line therapy for peripheral T-cell lymphoma and CD30-positive anaplastic large cell lymphoma. (
  • The lymphoma cells with this gene change have a marker on the surface called the CD30 antigen, which is also known as Ki-1 antigen. (
  • These CD30+ cells are CD4+ in most cases and are negative for epithelial membrane antigen (EMA) and anaplastic large cell lymphoma kinase (ALK). (
  • Systemic (nodal) anaplastic large cell lymphoma (ALCL) is a CD30 positive non-Hodgkin's lymphoma of T cell or null cell phenotype, mainly arising in lymph nodes. (
  • The invention describes a CAR which recognizes CD30 as a target antigen and initiates lysis of CD30-positive (CD30+) tumor cells but not of CD30+ healthy cells like hematopoietic stem cells. (
  • Upon binding to the target antigen, brentuximab vedotin is internalized and subsequently degraded within the lysosomal compartment. (
  • A great amount of non-specific binding causes high background staining which will mask the detection of the target antigen. (
  • Choice of the appropriate target antigen is a critical parameter that affects the efficacy, therapeutic window, and toxicity profile of ADCs. (
  • The mAb circulates throughout the body until it can find and hook onto the target antigen. (
  • Unlike systemic ALCL, it is negative for epithelial membrane antigen (EMA) and it does not express ALK. (
  • Their immunophenotypic expression was CD30 (Ki-1) and epithelial membrane antigen. (
  • Immunohistochemically, yolk sac tumors stain negative for epithelial membrane antigen and CK 7, and are only focally positive for Leu-M1 in 60% of cases. (
  • Choriocarcinomas stain positive for IHC markers cytokeratin, CD10, human placental lactogen, and epithelial membrane antigen, and negative for CD 31 and CD 34. (
  • One such marker is MUC1 mucin, also known as epithelial membrane antigen (EMA). (
  • In Hodgkin's disease, CD30/Ki-1 antigen is expressed by mononuclear-Hodgkin and multinucleated Reed-Sternberg cells. (
  • 16 This mechanism of action explains the high specific potency of this construct, both in preclinical in-vitro models as well as in animals bearing human Hodgkin's and other CD30-positive xenografts. (
  • The CD30 (Ki-1) molecule was identified by a monoclonal antibody which was originally found to react with an epitop present in Hodgkin's and Reed-Sternberg cells in Hodgkin's disease. (
  • In pathological conditions, CD30 positivity is regarded as a peculiar attribute of Hodgkin's and Reed-Sternberg cells. (
  • To enhance the antitumor activity of CD30-directed therapy, the antitubulin agent monomethyl auristatin E (MMAE) was attached to a CD30-specific monoclonal antibody by an enzyme-cleavable linker, producing the antibody-drug conjugate brentuximab vedotin (SGN-35). (
  • Retreatment arm: Patients with CD30-positive hematologic malignancies who experienced a complete remission (CR) or partial remission (PR) with previous brentuximab vedotin treatment on a clinical study and subsequently experienced disease progression or relapse. (
  • Extension treatment arm: Patients with either CD30-positive hematologic or nonhematologic malignancies who completed treatment in a prior brentuximab vedotin study without unacceptable toxicity and experienced clinical benefit as assessed by the investigator. (
  • CD30 is the target of the FDA approved therapeutic brentuximab vedotin (Adcetris). (
  • ADCETRIS™ (brentuximab vedotin) is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a potent, synthetic drug, monomethyl auristatin E (MMAE) utilizing Seattle Genetics' proprietary technology. (
  • Brentuximab vedotin (BV) is an antibody-drug conjugate that specifically delivers the potent cytotoxic drug monomethyl auristatin E (MMAE) to CD30-positive cells. (
  • Brentuximab vedotin (BV) is a novel therapeutic in the class of antibody-drug conjugates (ADC) that consists of three components: the cAC10 chimeric IgG1 antibody specific for CD30, the microtubule-disrupting agent monomethyl auristatin E (MMAE), and a protease-cleavable linker that covalently attaches MMAE to cAC10 ( 7 ). (
  • Brentuximab vedotin consists of the chimeric monoclonal antibody brentuximab (cAC10, which targets the cell-membrane protein CD30) linked with maleimide attachment groups, cathepsin-cleavable linkers (valine-citrulline), and para-aminobenzylcarbamate spacers to three to five units of the antimitotic agent monomethyl auristatin E (MMAE, reflected by the 'vedotin' in the drug's name). (
  • Reports in 2013, showed interim results from a Phase II, open-label, single-arm study designed to evaluate the antitumor activity of brentuximab vedotin in relapsed or refractory CD30-positive NHL, including B-cell neoplasms. (
  • Brentuximab vedotin (Adcetris ® ) , an antibody that targets the CD30 antigen (found on lymphocytes), attached to a chemo drug called MMAE . (
  • The cDNA cognate from the murine T cell clone 7B9 was expression cloned by using a chimeric probe with the extracellular region of CD30 linked to branched immunoglobulin heavy chains. (
  • A membrane-bound tumor necrosis family member found primarily on activated T-LYMPHOCYTES that binds specifically to CD30 ANTIGEN. (
  • Importantly, only a few activated lymphocytes and eosinophils physiologically express this antigen and there is very little cross-reactivity with vital organs. (
  • The lymph node processes and presents various antigens to either B or T lymphocytes. (
  • Type A is composed of lymphocytes, other inflammatory cells and large, atypical cells that are CD30 + and oftentimes Reed-Sternberg-like. (
  • Mice lacking bcl-2 have decreased numbers of lymphocytes ( 13 - 15 ) and conversely, bcl-2 transgenic mice have enhanced survival of antigen stimulated lymphocytes and prolonged immune responses ( 16 - 19 ). (
  • Alemtuzumab binds to the CD52 antigen, which is found on cells called lymphocytes (which include the leukemia cells). (
  • This is an antibody against the CD20 antigen, which is found on lymphocytes called B cells. (
  • As CD30 detection is important in the differential diagnosis of HD and ALCL, the expression of CD30 in different non-lymphoid tissues was re-evaluated by immunohistology and in situ hybridization. (
  • The absence of CD30 expression in reactive and neoplastic macrophages does not favour the concept that HD and ALCL are derived from these cells. (
  • We conducted a phase I dose escalation study in which 9 patients with relapsed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30.CAR-Ts) encoding the CD28 costimulatory endodomain. (
  • Of 2 patients with ALCL, 1 had a CR that persisted 9 months after the fourth infusion of CD30.CAR-Ts. (
  • CD30.CAR-Ts are safe and can lead to clinical responses in patients with HL and ALCL, indicating that further assessment of this therapy is warranted. (
  • Both HD and ALCL are characterized by the strong expression of CD30 on the malignant cell surfaces. (
  • Primary cutaneous ALCL is part of the spectrum of CD30 + cutaneous lymphoproliferative disease and clinically overlaps with lymphomatoid papulosis ref (Kadin ME. (
  • Although loss of CD30 expression is a possible mode of BV resistance in ALCL in vitro models, this has not been confirmed in patients. (
  • Recognizes the human CD30 cell surface antigen at ~120kD. (
  • CD30 was originally identified as a cell surface antigen of Hodgkins and Reed-Sternberg cells using monoclonal antibody Ki-1. (
  • Specific genetic modifications of the anti-CD30 CAR ensure the specific targeting of CD30+ tumor cells and prevent unwanted side-effects. (
  • In vivo experiments provided evidence that the treatment with anti-CD30 T-cells has no unwanted impact on the endogenous immune system. (
  • 11 , 12 However, most of these first- and second-generation anti-CD30 immunoconjugates were either too immunogenic or not effective enough for further clinical development. (
  • Flow cytometry analysis (surface staining) of K562 cells added to human blood, with anti-CD30 (MEM-268) PE. (
  • The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD30 antibody linked to CD28 transmembrane domain/ endodomain and CD137 (4-1BB), CD3-zeta signaling domains. (
  • SGN-35 is an ADC comprising an anti-CD30 antibody attached by an enzyme cleavable linker to a potent, synthetic drug payload, monomethyl auristatin E (MMAE), using Seattle Genetics' proprietary technology. (
  • Visualising an antibody-antigen interaction can be accomplished in a number of ways, mainly either of the following: Chromogenic immunohistochemistry (CIH), wherein an antibody is conjugated to an enzyme, such as peroxidase (the combination being termed immunoperoxidase), that can catalyse a colour-producing reaction. (
  • We also compared the patterns of DNMT3L immunohistochemistry with those of CD30 and SOX2. (
  • Since then, several reports have been published describing CD30 expression in non-lymphoid tissues and malignancies, such as embryonal carcinomas (ECs), seminomas, cultivated macrophages, two histiocytic neoplasms, decidual cells, and mesotheliomas. (
  • Extra-lymphoid CD30 expression was found in 48/51 cases of EC or EC components of germ cell tumours, in decidual cells of 1/10 cases, in activated mesothelium in 16/28 pleural and peritoneal effusions, and in small foci of tumour cells in 2/8 mesotheliomas. (
  • This monoclonal antibody detects the CD30 antigen, a 105 kD transmembrane glycoprotein designated as Ki-1 and expressed by a subpopulation of plasma cells. (
  • Although CD30 may also be expressed by normal activated T cells, no patients developed impaired virus-specific immunity. (
  • The cells do not express B-cell lineage restricted antigens or kappa or lambda immunoglobulin light chains or T-cell lineage-restricted antigens. (
  • The cells do express activation antigens. (
  • We used our monoclonal model of germinal center maturation, CL-01 B cells, to investigate the role of CD30 in human B cell differentiation. (
  • CL- 01 cells are IgM + IgD + CD30 + and switch to IgG, IgA, and IgE when exposed to CD40L and IL-4. (
  • The physiological relevance of this phenomenon is emphasized by similar CD30-mediated effects in naive B cells. (
  • Our data suggest that CD30 critically regulates the CD40-mediated differentiation of non-antigen-selected human B cells. (
  • CD30 is normally expressed on antigen-stimulated Th cells and B cells (4 ‑ 6). (
  • CD30 contributes to thymic negative selection by inducing the apoptotic cell death of CD4+CD8+ T cells (10, 11). (
  • In B cells, CD30 ligation promotes cellular proliferation and antibody production in addition to the expression of CXCR4, CCL3, and CCL5 (5, 12). (
  • CD30 is expressed on the cell surface of activated T, B, and NK cells, and monocytes. (
  • The monoclonal antibody is connected to a cell-killing agent by a linker system that is designed to be stable in the bloodstream but to release the cell-killing agent into CD30-expressing cells, resulting in target cell death. (
  • They're designed to lock onto certain antigens that cancer cells make too much of. (
  • They then carry these cell-killing materials to the cancer cells and lock onto the antigen. (
  • This leads to the death of the cancer cells, with little to no effect on your normal cells that don't have the antigen. (
  • For instance, you may get alemtuzumab (Campath) if your cells have the CD52 antigen. (
  • Intriguingly, the B cells within the HL cell lines expressed immunoglobulin light chain, the memory B-cell antigen CD27, and the stem cell marker aldehyde dehydrogenase (ALDH) [ 13 ]. (
  • Of the seven FDA-approved ADCs, four target lineage-specific hematologic antigens that are not markedly differentially expressed in neoplastic versus nonneoplastic cells. (
  • In contrast, CD30 expression in normal tissues is limited to activated T cells, activated B cells, select thymocytes, and some vascular beds ( 2 ). (
  • The problem with this is that cancer cells are very diverse, so it's very difficult to find a cancer-specific antigen that's found in all cancer cells. (
  • However, cancer cells are derived from non-cancer cells, which *do* have specific antigens that can be used. (
  • This is contingent upon two things - (1) that specific tissues can be targeted, and (2) that cancer cells retain tissue specific antigens. (
  • LyP type C has a monotonous population or large clusters of CD30 + T cells with few admixed inflammatory cells and a clinical history of regression. (
  • Borderline lesions (sometimes called LyP type C) typically are 1-2 cm in size and have larger clusters of CD30 + cells than typically seen in LyP ref . (
  • The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells. (
  • This approach is intended to spare non-targeted cells and thus may help minimize the potential toxic effects of traditional chemotherapy while allowing for the selective targeting of CD30-expressing cancer cells, thus potentially enhancing the antitumor activity. (
  • But, the multidimensional interaction of tumor, tumor associated antigen (TAA) and normal tissue exacerbates the uncontrolled outcome of T cells gene therapy. (
  • Further refinement of the detailed B-cell origin of PEL cells may be provided by the study of phenotypic markers specifically associated with late stages of B-cell differentiation, such as the plasma cell-specific CD138 antigen recognized by the B-B4 monoclonal antibody (MoAb). (
  • Zeiser R, Nguyen VH, Hou JZ, Beilhack A, Zambricki E, Buess M, Contag CH, Negrin RS: Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease. (
  • By transgenic expression of ovalbumin (OVA) as a model self antigen in the β cells of the pancreas, we have shown that self tolerance can be maintained by the cross-presentation of this antigen on dendritic cells in the draining lymph nodes. (
  • Bim-deficient T cells were not deleted in response to cross-presented self-antigen, strongly implicating Bim as the pro-apoptotic mediator of cross-tolerance. (
  • CD8 T cells recognize antigen presented by MHC class I molecules. (
  • This creates the potential for autoimmunity when antigens whose expression is limited to peripheral tissues are cross-presented to autoreactive CD8 T cells. (
  • However, we have shown that cross-presentation of self antigen leads to deletion of naive, autoreactive CD8 T cells. (
  • Apoptosis is involved in many aspects of the control of peripheral T cell numbers including: normal cell turnover in naive (unimmunized) animals, reduction of the pool of activated, antigen-specific T cells at the termination of an immune response, and maintenance of peripheral tolerance to tissue antigens ( 7 , 8 ). (
  • We confirmed drug resistance by MTS assay and analyzed CD30 expression in resistant cells by flow cytometry, qRT-PCR, and Western blotting. (
  • Anti-CD70 antibody-drug conjugates (ADC) consisting of auristatin phenylalanine phenylenediamine (AFP) or monomethyl auristatin phenylalanine (MMAF), two novel derivatives of the anti-tubulin agent auristatin, mediated potent antigen-dependent cytotoxicity in CD70-expressing RCC cells. (
  • DNMT3L staining was more prominent and specific than CD30 or SOX2 staining for detecting EC cells. (
  • The antibody cAC10 part of the drug binds to CD30 which often occurs on diseased cells but rarely on normal tissues. (
  • The antibody portion of the drug attaches to CD30 on the surface of malignant cells, delivering MMAE which is responsible for the anti-tumour activity. (
  • HTLV-1-infected cells and ATL cells (partial) express CD30. (
  • Soluble CD30 (sCD30) may impair the interaction of CD30 ligand+ cells with CD30+ ATL cells. (
  • Thereafter monoclonal proliferation of infected cells following antigen presentation forms a local network between cytokines and cytokine receptors. (
  • CD30 expression is strictly dependent on activation and proliferation of T- and B-cells. (
  • Caligaris-Cappio F, Bertero MT, Converso M, Stacchini A, Vinante F, Romagnani S, Pizzolo G. Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. (
  • The neoplastic cells express the CD30 antigen, and show variable expression of T-cell markers. (
  • Its restricted expression on normal cells makes CD30 an attractive candidate for targeted therapy. (
  • Once attached, they can recruit other parts of the immune system to destroy the cells containing the antigen. (
  • Most naked mAbs attach to antigens on cancer cells, but some work by binding to antigens on other, non-cancerous cells, or even free-floating proteins. (
  • Other naked mAbs work mainly by attaching to and blocking antigens on cancer cells (or other nearby cells) that help cancer cells grow or spread. (
  • Type A is characterized by a a wedge-shaped diffuse dermal infiltrate containing scattered or clustered medium-sized to large pleomorphic or anaplastic lymphoid cells that are positive for CD30 (Figure 4). (
  • At immunophenotyping, cHL is typically CD15 + , CD30 +* , possibly EBER + , and CD20 -/+ (Olympus BX41 microscope, Olympus CAMEDIA C-7070 camera, magnification ×400, colours balanced after acquisition with Adobe Photoshop). (
  • A defining attribute of the Reed-Sternberg cell is its expression of the CD30 antigen. (
  • CD30 expression was not confirmed in 27 germ cell tumours of the testis without an EC component nor in cultivated macrophages and 17 histiocytic malignancies. (
  • Overexpression of CD30 antigen in hematopoietic malignancies make the antigen clinically useful as a biological tumor marker. (
  • Mature human CD30 consists of a 361 amino acid (aa) extracellular domain (ECD) with six cysteine-rich repeats, a 28 aa transmembrane segment, and a 188 aa cytoplasmic domain (3). (
  • Characterization of the CD30 antigen has shown it to be in its mature form a transmembrane protein of about 120 kDa elaborated from an 84 kDa cytoplasmic precursor primarily through glycosylation. (
  • This antibody-drug conjugate consists of a humanized monoclonal antibody targeting CD30 that is linked via a protease-sensitive dipeptide to monomethyl-auristatin-E, a potent cytostatic tubulin inhibitor. (
  • Target selection for antibody-drug conjugates (ADC) frequently focuses on identifying antigens with differential expression in tumor and normal tissue, to mitigate the risk of on-target toxicity. (
  • The binding of CD30 to CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation, and apoptotic cell death. (
  • Recognizes a single chain glycoprotein of 105/120kDa, identified as CD30/Ki-1. (
  • CD30 is synthesized as a 90kDa precursor, which is processed in the Golgi complex into a membrane-bound phosphorylated mature 105/120kDa glycoprotein. (
  • Access of antigen to the MHC class I presentation pathway was originally thought to be restricted to endogenous proteins, i.e., those expressed within the cytoplasm of the cell presenting the antigen. (
  • All of them hit normal tissue antigens that are either overexpressed on cancer or more important to cancer. (
  • Tissue Antigens , 60 , 139-146. (
  • An 85 ‑ 90 kDa soluble form of CD30 is shed from the cell surface by TACE-mediated cleavage (13, 14). (
  • Pavlov I, Martins TB, Delgado JC: Development and validation of a fluorescent microsphere immunoassay for soluble CD30 testing. (
  • An 85 kDa soluble form of the CD30 molecule (sCD30) has been shown to be released by CD30+ cell in vitro and in vivo. (
  • Chilosi M, Facchetti F, Notarangelo LD, Romagnani S, Del Prete G, Almerigogna F, De Carli M, Pizzolo G. CD30 cell expression and abnormal soluble CD30 serum accumulation in Omenn's syndrome: evidence for a T helper 2-mediated condition. (
  • Soluble form of CD30 (sCD30) serves as a marker reflecting Th2 immune response. (
  • A recombinant protein fragment specific to CD30 was used as the immunogen for the C30/412 antibody. (
  • The immunogen for this antibody was CD30. (
  • In reactive lymphoid tissue, CD30 is expressed only in a small population of activated lymphoid blasts. (
  • CD30 is a lymphocyte activation antigen, related to tumor necrosis factor. (
  • Inotuzumab ozogamicin targets CD22, a B-cell lineage antigen, and is approved for B-cell precursor acute lymphoblastic leukemia ( 7 ). (
  • Gentuzumab ozogamicin targets CD33, a myeloid lineage antigen, and is approved for acute myeloid leukemia ( 8 ). (
  • Kadcyla, which targets the HER2 antigen, is being evaluated in seven Phase III clinical trials, as well as in earlier-stage trials. (
  • Alternate splicing of human CD30 generates an isoform that includes only the C‑terminal 132 aa of the cytoplasmic domain. (
  • CD30 is a cell membrane protein. (
  • An antibody is a protein that sticks to a specific protein called an antigen . (
  • Influence of immunosuppressive drugs on the CD30 molecule in kidney transplanted patients. (
  • There is growing evidence for a potential role of the CD30 molecule in clinical use and therapy. (
  • CD30 acts as a costimulatory molecule in thymic negative selection. (